CINXE.COM
December 2021 - Lexaria Bioscience
<!DOCTYPE html> <html lang="en-US" class="no-js"> <head> <meta charset="UTF-8"> <meta name="SKYPE_TOOLBAR" content="SKYPE_TOOLBAR_PARSER_COMPATIBLE" /> <link rel="profile" href="https://gmpg.org/xfn/11"> <meta name="viewport" content="width=device-width, initial-scale=1"> <script> 'use strict'; (function(html){html.className = html.className.replace(/\bno-js\b/,'js')})(document.documentElement);</script> <meta name='robots' content='noindex, follow' /> <style>img:is([sizes="auto" i], [sizes^="auto," i]) { contain-intrinsic-size: 3000px 1500px }</style> <!-- This site is optimized with the Yoast SEO plugin v24.4 - https://yoast.com/wordpress/plugins/seo/ --> <title>December 2021 - Lexaria Bioscience</title> <meta property="og:locale" content="en_US" /> <meta property="og:type" content="website" /> <meta property="og:title" content="December 2021 - Lexaria Bioscience" /> <meta property="og:url" content="https://lexariabioscience.com/2021/12/" /> <meta property="og:site_name" content="Lexaria Bioscience" /> <meta name="twitter:card" content="summary_large_image" /> <script type="application/ld+json" class="yoast-schema-graph">{"@context":"https://schema.org","@graph":[{"@type":"CollectionPage","@id":"https://lexariabioscience.com/2021/12/","url":"https://lexariabioscience.com/2021/12/","name":"December 2021 - Lexaria Bioscience","isPartOf":{"@id":"https://lexariabioscience.com/#website"},"breadcrumb":{"@id":"https://lexariabioscience.com/2021/12/#breadcrumb"},"inLanguage":"en-US"},{"@type":"BreadcrumbList","@id":"https://lexariabioscience.com/2021/12/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://lexariabioscience.com/"},{"@type":"ListItem","position":2,"name":"Archives for December 2021"}]},{"@type":"WebSite","@id":"https://lexariabioscience.com/#website","url":"https://lexariabioscience.com/","name":"Lexaria Bioscience","description":"","publisher":{"@id":"https://lexariabioscience.com/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https://lexariabioscience.com/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https://lexariabioscience.com/#organization","name":"Lexaria Bioscience","url":"https://lexariabioscience.com/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https://lexariabioscience.com/#/schema/logo/image/","url":"http://lexariabioscience.com/wp-content/uploads/2022/03/Lexaria_Bioscience_Logo_Dark_WEB.png","contentUrl":"http://lexariabioscience.com/wp-content/uploads/2022/03/Lexaria_Bioscience_Logo_Dark_WEB.png","width":418,"height":220,"caption":"Lexaria Bioscience"},"image":{"@id":"https://lexariabioscience.com/#/schema/logo/image/"}}]}</script> <!-- / Yoast SEO plugin. --> <link rel='dns-prefetch' href='//www.googletagmanager.com' /> <link rel='dns-prefetch' href='//fonts.googleapis.com' /> <link href='//hb.wpmucdn.com' rel='preconnect' /> <link href="https://fonts.googleapis.com" rel='preconnect' /> <link href='//fonts.gstatic.com' crossorigin='' rel='preconnect' /> <link rel="alternate" type="application/rss+xml" title="Lexaria Bioscience » Feed" href="https://lexariabioscience.com/feed/" /> <link rel="alternate" type="application/rss+xml" title="Lexaria Bioscience » Comments Feed" href="https://lexariabioscience.com/comments/feed/" /> <script> /* <![CDATA[ */ window._wpemojiSettings = {"baseUrl":"https:\/\/s.w.org\/images\/core\/emoji\/15.0.3\/72x72\/","ext":".png","svgUrl":"https:\/\/s.w.org\/images\/core\/emoji\/15.0.3\/svg\/","svgExt":".svg","source":{"concatemoji":"https:\/\/lexariabioscience.com\/wp-includes\/js\/wp-emoji-release.min.js?ver=6.7.2"}}; /*! This file is auto-generated */ !function(i,n){var o,s,e;function c(e){try{var t={supportTests:e,timestamp:(new Date).valueOf()};sessionStorage.setItem(o,JSON.stringify(t))}catch(e){}}function p(e,t,n){e.clearRect(0,0,e.canvas.width,e.canvas.height),e.fillText(t,0,0);var t=new Uint32Array(e.getImageData(0,0,e.canvas.width,e.canvas.height).data),r=(e.clearRect(0,0,e.canvas.width,e.canvas.height),e.fillText(n,0,0),new Uint32Array(e.getImageData(0,0,e.canvas.width,e.canvas.height).data));return t.every(function(e,t){return e===r[t]})}function u(e,t,n){switch(t){case"flag":return n(e,"\ud83c\udff3\ufe0f\u200d\u26a7\ufe0f","\ud83c\udff3\ufe0f\u200b\u26a7\ufe0f")?!1:!n(e,"\ud83c\uddfa\ud83c\uddf3","\ud83c\uddfa\u200b\ud83c\uddf3")&&!n(e,"\ud83c\udff4\udb40\udc67\udb40\udc62\udb40\udc65\udb40\udc6e\udb40\udc67\udb40\udc7f","\ud83c\udff4\u200b\udb40\udc67\u200b\udb40\udc62\u200b\udb40\udc65\u200b\udb40\udc6e\u200b\udb40\udc67\u200b\udb40\udc7f");case"emoji":return!n(e,"\ud83d\udc26\u200d\u2b1b","\ud83d\udc26\u200b\u2b1b")}return!1}function f(e,t,n){var r="undefined"!=typeof WorkerGlobalScope&&self instanceof WorkerGlobalScope?new OffscreenCanvas(300,150):i.createElement("canvas"),a=r.getContext("2d",{willReadFrequently:!0}),o=(a.textBaseline="top",a.font="600 32px Arial",{});return e.forEach(function(e){o[e]=t(a,e,n)}),o}function t(e){var t=i.createElement("script");t.src=e,t.defer=!0,i.head.appendChild(t)}"undefined"!=typeof Promise&&(o="wpEmojiSettingsSupports",s=["flag","emoji"],n.supports={everything:!0,everythingExceptFlag:!0},e=new Promise(function(e){i.addEventListener("DOMContentLoaded",e,{once:!0})}),new Promise(function(t){var n=function(){try{var e=JSON.parse(sessionStorage.getItem(o));if("object"==typeof e&&"number"==typeof e.timestamp&&(new Date).valueOf()<e.timestamp+604800&&"object"==typeof e.supportTests)return e.supportTests}catch(e){}return null}();if(!n){if("undefined"!=typeof Worker&&"undefined"!=typeof OffscreenCanvas&&"undefined"!=typeof URL&&URL.createObjectURL&&"undefined"!=typeof Blob)try{var e="postMessage("+f.toString()+"("+[JSON.stringify(s),u.toString(),p.toString()].join(",")+"));",r=new Blob([e],{type:"text/javascript"}),a=new Worker(URL.createObjectURL(r),{name:"wpTestEmojiSupports"});return void(a.onmessage=function(e){c(n=e.data),a.terminate(),t(n)})}catch(e){}c(n=f(s,u,p))}t(n)}).then(function(e){for(var t in e)n.supports[t]=e[t],n.supports.everything=n.supports.everything&&n.supports[t],"flag"!==t&&(n.supports.everythingExceptFlag=n.supports.everythingExceptFlag&&n.supports[t]);n.supports.everythingExceptFlag=n.supports.everythingExceptFlag&&!n.supports.flag,n.DOMReady=!1,n.readyCallback=function(){n.DOMReady=!0}}).then(function(){return e}).then(function(){var e;n.supports.everything||(n.readyCallback(),(e=n.source||{}).concatemoji?t(e.concatemoji):e.wpemoji&&e.twemoji&&(t(e.twemoji),t(e.wpemoji)))}))}((window,document),window._wpemojiSettings); /* ]]> */ </script> <link rel='stylesheet' id='cnss_font_awesome_css-css' href='https://lexariabioscience.com/wp-content/plugins/easy-social-icons/css/font-awesome/css/all.min.css?ver=5.7.2' media='all' /> <link rel='stylesheet' id='cnss_font_awesome_v4_shims-css' href='https://lexariabioscience.com/wp-content/plugins/easy-social-icons/css/font-awesome/css/v4-shims.min.css?ver=5.7.2' media='all' /> <link rel='stylesheet' id='cnss_css-css' href='https://lexariabioscience.com/wp-content/plugins/easy-social-icons/css/cnss.css?ver=1.0' media='all' /> <style id='wp-emoji-styles-inline-css'> img.wp-smiley, img.emoji { display: inline !important; border: none !important; box-shadow: none !important; height: 1em !important; width: 1em !important; margin: 0 0.07em !important; vertical-align: -0.1em !important; background: none !important; padding: 0 !important; } </style> <link rel='stylesheet' id='wp-block-library-css' href='https://lexariabioscience.com/wp-includes/css/dist/block-library/style.min.css?ver=6.7.2' media='all' /> <style id='classic-theme-styles-inline-css'> /*! This file is auto-generated */ .wp-block-button__link{color:#fff;background-color:#32373c;border-radius:9999px;box-shadow:none;text-decoration:none;padding:calc(.667em + 2px) calc(1.333em + 2px);font-size:1.125em}.wp-block-file__button{background:#32373c;color:#fff;text-decoration:none} </style> <style id='global-styles-inline-css'> :root{--wp--preset--aspect-ratio--square: 1;--wp--preset--aspect-ratio--4-3: 4/3;--wp--preset--aspect-ratio--3-4: 3/4;--wp--preset--aspect-ratio--3-2: 3/2;--wp--preset--aspect-ratio--2-3: 2/3;--wp--preset--aspect-ratio--16-9: 16/9;--wp--preset--aspect-ratio--9-16: 9/16;--wp--preset--color--black: #000000;--wp--preset--color--cyan-bluish-gray: #abb8c3;--wp--preset--color--white: #ffffff;--wp--preset--color--pale-pink: #f78da7;--wp--preset--color--vivid-red: #cf2e2e;--wp--preset--color--luminous-vivid-orange: #ff6900;--wp--preset--color--luminous-vivid-amber: #fcb900;--wp--preset--color--light-green-cyan: #7bdcb5;--wp--preset--color--vivid-green-cyan: #00d084;--wp--preset--color--pale-cyan-blue: #8ed1fc;--wp--preset--color--vivid-cyan-blue: #0693e3;--wp--preset--color--vivid-purple: #9b51e0;--wp--preset--gradient--vivid-cyan-blue-to-vivid-purple: linear-gradient(135deg,rgba(6,147,227,1) 0%,rgb(155,81,224) 100%);--wp--preset--gradient--light-green-cyan-to-vivid-green-cyan: linear-gradient(135deg,rgb(122,220,180) 0%,rgb(0,208,130) 100%);--wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange: linear-gradient(135deg,rgba(252,185,0,1) 0%,rgba(255,105,0,1) 100%);--wp--preset--gradient--luminous-vivid-orange-to-vivid-red: linear-gradient(135deg,rgba(255,105,0,1) 0%,rgb(207,46,46) 100%);--wp--preset--gradient--very-light-gray-to-cyan-bluish-gray: linear-gradient(135deg,rgb(238,238,238) 0%,rgb(169,184,195) 100%);--wp--preset--gradient--cool-to-warm-spectrum: linear-gradient(135deg,rgb(74,234,220) 0%,rgb(151,120,209) 20%,rgb(207,42,186) 40%,rgb(238,44,130) 60%,rgb(251,105,98) 80%,rgb(254,248,76) 100%);--wp--preset--gradient--blush-light-purple: linear-gradient(135deg,rgb(255,206,236) 0%,rgb(152,150,240) 100%);--wp--preset--gradient--blush-bordeaux: linear-gradient(135deg,rgb(254,205,165) 0%,rgb(254,45,45) 50%,rgb(107,0,62) 100%);--wp--preset--gradient--luminous-dusk: linear-gradient(135deg,rgb(255,203,112) 0%,rgb(199,81,192) 50%,rgb(65,88,208) 100%);--wp--preset--gradient--pale-ocean: linear-gradient(135deg,rgb(255,245,203) 0%,rgb(182,227,212) 50%,rgb(51,167,181) 100%);--wp--preset--gradient--electric-grass: linear-gradient(135deg,rgb(202,248,128) 0%,rgb(113,206,126) 100%);--wp--preset--gradient--midnight: linear-gradient(135deg,rgb(2,3,129) 0%,rgb(40,116,252) 100%);--wp--preset--font-size--small: 13px;--wp--preset--font-size--medium: 20px;--wp--preset--font-size--large: 36px;--wp--preset--font-size--x-large: 42px;--wp--preset--spacing--20: 0.44rem;--wp--preset--spacing--30: 0.67rem;--wp--preset--spacing--40: 1rem;--wp--preset--spacing--50: 1.5rem;--wp--preset--spacing--60: 2.25rem;--wp--preset--spacing--70: 3.38rem;--wp--preset--spacing--80: 5.06rem;--wp--preset--shadow--natural: 6px 6px 9px rgba(0, 0, 0, 0.2);--wp--preset--shadow--deep: 12px 12px 50px rgba(0, 0, 0, 0.4);--wp--preset--shadow--sharp: 6px 6px 0px rgba(0, 0, 0, 0.2);--wp--preset--shadow--outlined: 6px 6px 0px -3px rgba(255, 255, 255, 1), 6px 6px rgba(0, 0, 0, 1);--wp--preset--shadow--crisp: 6px 6px 0px rgba(0, 0, 0, 1);}:where(.is-layout-flex){gap: 0.5em;}:where(.is-layout-grid){gap: 0.5em;}body .is-layout-flex{display: flex;}.is-layout-flex{flex-wrap: wrap;align-items: center;}.is-layout-flex > :is(*, div){margin: 0;}body .is-layout-grid{display: grid;}.is-layout-grid > :is(*, div){margin: 0;}:where(.wp-block-columns.is-layout-flex){gap: 2em;}:where(.wp-block-columns.is-layout-grid){gap: 2em;}:where(.wp-block-post-template.is-layout-flex){gap: 1.25em;}:where(.wp-block-post-template.is-layout-grid){gap: 1.25em;}.has-black-color{color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-color{color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-color{color: var(--wp--preset--color--white) !important;}.has-pale-pink-color{color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-color{color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-color{color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-color{color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-color{color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-color{color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-color{color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-color{color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-color{color: var(--wp--preset--color--vivid-purple) !important;}.has-black-background-color{background-color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-background-color{background-color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-background-color{background-color: var(--wp--preset--color--white) !important;}.has-pale-pink-background-color{background-color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-background-color{background-color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-background-color{background-color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-background-color{background-color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-background-color{background-color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-background-color{background-color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-background-color{background-color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-background-color{background-color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-background-color{background-color: var(--wp--preset--color--vivid-purple) !important;}.has-black-border-color{border-color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-border-color{border-color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-border-color{border-color: var(--wp--preset--color--white) !important;}.has-pale-pink-border-color{border-color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-border-color{border-color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-border-color{border-color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-border-color{border-color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-border-color{border-color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-border-color{border-color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-border-color{border-color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-border-color{border-color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-border-color{border-color: var(--wp--preset--color--vivid-purple) !important;}.has-vivid-cyan-blue-to-vivid-purple-gradient-background{background: var(--wp--preset--gradient--vivid-cyan-blue-to-vivid-purple) !important;}.has-light-green-cyan-to-vivid-green-cyan-gradient-background{background: var(--wp--preset--gradient--light-green-cyan-to-vivid-green-cyan) !important;}.has-luminous-vivid-amber-to-luminous-vivid-orange-gradient-background{background: var(--wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange) !important;}.has-luminous-vivid-orange-to-vivid-red-gradient-background{background: var(--wp--preset--gradient--luminous-vivid-orange-to-vivid-red) !important;}.has-very-light-gray-to-cyan-bluish-gray-gradient-background{background: var(--wp--preset--gradient--very-light-gray-to-cyan-bluish-gray) !important;}.has-cool-to-warm-spectrum-gradient-background{background: var(--wp--preset--gradient--cool-to-warm-spectrum) !important;}.has-blush-light-purple-gradient-background{background: var(--wp--preset--gradient--blush-light-purple) !important;}.has-blush-bordeaux-gradient-background{background: var(--wp--preset--gradient--blush-bordeaux) !important;}.has-luminous-dusk-gradient-background{background: var(--wp--preset--gradient--luminous-dusk) !important;}.has-pale-ocean-gradient-background{background: var(--wp--preset--gradient--pale-ocean) !important;}.has-electric-grass-gradient-background{background: var(--wp--preset--gradient--electric-grass) !important;}.has-midnight-gradient-background{background: var(--wp--preset--gradient--midnight) !important;}.has-small-font-size{font-size: var(--wp--preset--font-size--small) !important;}.has-medium-font-size{font-size: var(--wp--preset--font-size--medium) !important;}.has-large-font-size{font-size: var(--wp--preset--font-size--large) !important;}.has-x-large-font-size{font-size: var(--wp--preset--font-size--x-large) !important;} :where(.wp-block-post-template.is-layout-flex){gap: 1.25em;}:where(.wp-block-post-template.is-layout-grid){gap: 1.25em;} :where(.wp-block-columns.is-layout-flex){gap: 2em;}:where(.wp-block-columns.is-layout-grid){gap: 2em;} :root :where(.wp-block-pullquote){font-size: 1.5em;line-height: 1.6;} </style> <link rel='stylesheet' id='contact-form-7-css' href='https://lexariabioscience.com/wp-content/plugins/contact-form-7/includes/css/styles.css?ver=6.0.3' media='all' /> <link rel='stylesheet' id='font-awesome-css' href='https://lexariabioscience.com/wp-content/plugins/themestek-labtechco-extras/icon-picker/icon-libraries/font-awesome/css/font-awesome.min.css?ver=6.7.2' media='all' /> <link rel='stylesheet' id='themify-css' href='https://lexariabioscience.com/wp-content/plugins/themestek-labtechco-extras/icon-picker/icon-libraries/themify-icons/themify-icons.css?ver=6.7.2' media='all' /> <link rel='stylesheet' id='sgicon-css' href='https://lexariabioscience.com/wp-content/plugins/themestek-labtechco-extras/icon-picker/icon-libraries/stroke-gap-icons/style.css?ver=6.7.2' media='all' /> <link rel='stylesheet' id='vc_linecons-css' href='https://lexariabioscience.com/wp-content/plugins/js_composer/assets/css/lib/vc-linecons/vc_linecons_icons.min.css?ver=7.7.2' media='all' /> <link rel='stylesheet' id='ts_labtechco_business_icon-css' href='https://lexariabioscience.com/wp-content/plugins/themestek-labtechco-extras/icon-picker/icon-libraries/ts-lab-icons/font/flaticon.css?ver=6.7.2' media='all' /> <link rel='stylesheet' id='ts-cs-google-fonts-css' href='//fonts.googleapis.com/css?family=Poppins%3A300%2C400%2C500%2C600%2C700%7CArimo%3A400%7CVollkorn%3A700%7CRoboto+Condensed%3A300%2C300italic%2C400%2Citalic%2C700%2C700italic%7CRoboto%3A500&ver=1.0.0' media='all' /> <link rel='stylesheet' id='ts-base-icons-css' href='https://lexariabioscience.com/wp-content/themes/labtechco/libraries/ts-labtechco-icons/css/ts-labtechco-icons.css?ver=6.7.2' media='all' /> <link rel='stylesheet' id='perfect-scrollbar-css' href='https://lexariabioscience.com/wp-content/themes/labtechco/libraries/perfect-scrollbar/perfect-scrollbar.min.css?ver=6.7.2' media='all' /> <link rel='stylesheet' id='chrisbracco-tooltip-css' href='https://lexariabioscience.com/wp-content/themes/labtechco/libraries/chrisbracco-tooltip/chrisbracco-tooltip.min.css?ver=6.7.2' media='all' /> <link rel='stylesheet' id='multi-columns-row-css' href='https://lexariabioscience.com/wp-content/themes/labtechco/css/multi-columns-row.css?ver=6.7.2' media='all' /> <link rel='stylesheet' id='ts-select2-css' href='https://lexariabioscience.com/wp-content/themes/labtechco/libraries/select2/select2.min.css?ver=6.7.2' media='all' /> <link rel='stylesheet' id='flexslider-css' href='https://lexariabioscience.com/wp-content/plugins/js_composer/assets/lib/vendor/node_modules/flexslider/flexslider.min.css?ver=7.7.2' media='all' /> <link rel='stylesheet' id='slick-css' href='https://lexariabioscience.com/wp-content/themes/labtechco/libraries/slick/slick.css?ver=6.7.2' media='all' /> <link rel='stylesheet' id='slick-theme-css' href='https://lexariabioscience.com/wp-content/themes/labtechco/libraries/slick/slick-theme.css?ver=6.7.2' media='all' /> <link rel='stylesheet' id='prettyphoto-css' href='https://lexariabioscience.com/wp-content/plugins/js_composer/assets/lib/vendor/prettyphoto/css/prettyPhoto.min.css?ver=7.7.2' media='all' /> <link rel='stylesheet' id='bootstrap-css' href='https://lexariabioscience.com/wp-content/themes/labtechco/css/bootstrap.min.css?ver=6.7.2' media='all' /> <link rel='stylesheet' id='bootstrap-theme-css' href='https://lexariabioscience.com/wp-content/themes/labtechco/css/bootstrap-theme.min.css?ver=6.7.2' media='all' /> <link rel='stylesheet' id='labtechco-core-style-css' href='https://lexariabioscience.com/wp-content/themes/labtechco/css/core.min.css?ver=6.7.2' media='all' /> <link rel='stylesheet' id='js_composer_front-css' href='https://lexariabioscience.com/wp-content/plugins/js_composer/assets/css/js_composer.min.css?ver=7.7.2' media='all' /> <link rel='stylesheet' id='labtechco-master-style-css' href='https://lexariabioscience.com/wp-content/themes/labtechco/css/master.min.css?ver=6.7.2' media='all' /> <link rel='stylesheet' id='labtechco-responsive-style-css' href='https://lexariabioscience.com/wp-content/themes/labtechco/css/responsive.min.css?ver=6.7.2' media='all' /> <link rel='stylesheet' id='tste-labtechco-theme-style-css' href='https://lexariabioscience.com/wp-admin/admin-ajax.php?action=themestek_theme_css&ver=6.7.2' media='all' /> <script src="https://lexariabioscience.com/wp-includes/js/jquery/jquery.min.js?ver=3.7.1" id="jquery-core-js"></script> <script src="https://lexariabioscience.com/wp-includes/js/jquery/jquery-migrate.min.js?ver=3.4.1" id="jquery-migrate-js"></script> <script src="https://lexariabioscience.com/wp-content/plugins/easy-social-icons/js/cnss.js?ver=1.0" id="cnss_js-js"></script> <script src="https://lexariabioscience.com/wp-content/plugins/b2i-investor-tools/js/wb_script.js?ver=1.0.7.9" id="whistleblower-js"></script> <script src="https://lexariabioscience.com/wp-content/plugins/themestek-labtechco-extras/js/jquery-resize.min.js?ver=6.7.2" id="jquery-resize-js"></script> <!-- Google tag (gtag.js) snippet added by Site Kit --> <!-- Google Analytics snippet added by Site Kit --> <script src="https://www.googletagmanager.com/gtag/js?id=GT-NSVFNVV" id="google_gtagjs-js" async></script> <script id="google_gtagjs-js-after"> /* <![CDATA[ */ window.dataLayer = window.dataLayer || [];function gtag(){dataLayer.push(arguments);} gtag("set","linker",{"domains":["lexariabioscience.com"]}); gtag("js", new Date()); gtag("set", "developer_id.dZTNiMT", true); gtag("config", "GT-NSVFNVV"); /* ]]> */ </script> <!-- End Google tag (gtag.js) snippet added by Site Kit --> <script></script><link rel="https://api.w.org/" href="https://lexariabioscience.com/wp-json/" /><link rel="EditURI" type="application/rsd+xml" title="RSD" href="https://lexariabioscience.com/xmlrpc.php?rsd" /> <meta name="generator" content="WordPress 6.7.2" /> <!-- start Simple Custom CSS and JS --> <style> .investor-menu.sticky-nav {position: fixed; left: 0; right: 0; margin-left: auto; margin-right: auto; background-color: transparent !important; width: 100%; z-index: 999; top: 60px;} .investor-menu.sticky-nav #menu-investors {background-color: #3A5DAE !important;} .investor-menu.sticky-nav .container {padding-left: 0; padding-right: 0;}</style> <!-- end Simple Custom CSS and JS --> <!-- start Simple Custom CSS and JS --> <style> @media (max-width:844px) { div.investor-menu ul.menu li ul.sub-menu {display: block !important;} ul.sub-menu li {min-width: 100% !important; display: block !important; padding: 5px 0px;} ul.sub-menu {background: transparent !important; padding-left: 30px !important; margin-top: 5px !important;} .investor-menu li a {padding: 0 !important;} .investor-menu li {padding: 5px 0px;} .team-layout3.dir-item-wrap {min-width: 100%;} .team-layout3 .modal-window {min-width: 100%;} .news-right-btn {text-align: left !important;} .b2iHeadLinesHeadlineCell.b2iPlugInHeadLinesHeadlineCell {padding-bottom: 0 !important;} .full-row-grey .vc_row.container {max-width: 90%;} .latest-annual-section {text-align: center;} .latest-annual-section .SECLayout22PDF-formLinks {text-align: center !important;} .email-alerts-section h3 {text-align: center;} .company-overview-section h3 {line-height: 1.2em;} .company-overview-section .btn {min-width: 100%; margin-bottom: 5px;} }</style> <!-- end Simple Custom CSS and JS --> <!-- start Simple Custom CSS and JS --> <style> #LibStoryDiv a {text-decoration: underline;} /* Contact */ @media (min-width:844px) { #b2iContact .b2iFormLabel {min-width: 100%; clear: both;} #b2iContact input, #b2iContact select, #b2iContact textarea {min-width: 100%; min-height: 45px;} #b2iContact #ContactEmail, #b2iContact #ContactCompany, #b2iContact #ContactMessage {min-width: 98% !important;} #b2iContact #b2iContactFirstNameRow, #b2iContact #b2iContactLastNameRow, #b2iContact #b2iContactRoleRow, #b2iContact #b2iContactPhoneRow {width: 48%; clear: none; display: inline-block;} #b2iContact #b2iContactFirstNameRow, #b2iContact #b2iContactRoleRow {margin-right: 1.5% !important;} #b2iContact #b2iContactSubmit {min-width: 200px; margin-top: 20px; margin-bottom: 20px;} #b2iContact .b2iFormLabel {font-weight:bold; margin-bottom: 5px; margin-top: 10px;} } @media (max-width:844px) { #b2iContact input, #b2iContact select, #b2iContact textarea {min-width: 100%; min-height: 45px;} #b2iContact #ContactEmail, #b2iContact #ContactCompany, #b2iContact #ContactMessage {min-width: 100% !important;} #b2iContact #b2iContactSubmit {margin-top: 20px; margin-bottom: 20px;} } #b2iContactSubmit {border: 1px solid #000; background: transparent; color: #000; font-size: 18px; cursor: pointer;} /* Email signup */ @media (min-width:844px) { #b2iEmailSignUp {width: 100%;} .b2iEmailDiv, .b2iFirstNameDiv, .b2iLastNameDiv, .b2iCompanyDiv {display: inline-block; width: 49%;} .b2iEmailInput {min-width: 95%;} }</style> <!-- end Simple Custom CSS and JS --> <!-- start Simple Custom CSS and JS --> <style> .single .ts-titlebar-main-inner .entry-title {font-size: 30px; line-height: 1.3em;} .ir-contact-3-col {font-size: 16px !important;} @media (min-width:844px) { #LibStoryContainer {margin-top: 50px;} .investor-menu a {padding: 18px 8px !important; } .sub-menu {background: #f5f5f5 !important; box-shadow: 0 6px 12px rgba(0,0,0,.175);} .sub-menu a {color: #031b4e !important;} .sub-menu li {min-width: 100%; border-bottom: 1px solid #ddd;} .sub-menu .current-menu-item {background: #FFF !important;} .view-all-button {background: ##EBEFF7 !important; text-align: center; margin-top: -80px; padding: 0 0 50px 0px!important;} .view-all-button .vc_row.container .btn {margin-bottom: -30px !important;} } @media (max-width: 844px) { .view-all-button {background: ##EBEFF7 !important; text-align: center; margin-top: -120px; padding: 0 0 50px 0px!important;} .view-all-button .vc_row.container .btn {margin-bottom: -30px !important;} .page-id-8559 #DocItem76967, .page-id-8703 #DocItem76967 {min-width: 100% !important;} .DocItemImage {padding: 0 !important;} #DocItemTitle76967, #DocItemTitle76968 {text-align: center;} } #b2iLibNav {margin-top: 50px;} #b2iLibNav a {text-decoration: underline;} /* Tabs */ .vc_tta-tabs-list {border-bottom: 2px solid #3A5DAE !important;} .vc_tta-tabs-list .vc_tta-tab {color: #031b4e; border-left:2px solid #3A5DAE; border-top: 2px solid #3A5DAE; border-right: 2px solid #3A5DAE;} .vc_tta-tabs-list .vc_tta-tab.vc_active span {color: #FFF;} .vc_tta-tabs-list .vc_tta-tab a {border-radius: 0 !important;} .vc_tta-tabs-list .vc_tta-tab.vc_active, .vc_tta-tabs-list .vc_tta-tab.vc_active a {background: #3A5DAE !important;} #DocItem76968 img {width: 100%;} .DocItemImage {width: 100% !important; max-width: 100% !important;} .DocItem8 {padding: 0 !important; margin: 0 !important; max-width: 100% !important; width: 100% !important;} #DocItemTitle76968 { background: #3A5DAE; padding: 15px 0px; } #DocItemTitle76968 a { color: #FFF; } .page-id-8559 #DocItem76967, .page-id-8703 #DocItem76967 {min-width: 350px;} #DocItem76967 img {width: 100%;} #DocItem76967 {min-width: 100%; padding: 0; margin: 0;} #DocItemTitle76967 {background: #3A5DAE; padding: 15px 0px;} #DocItemTitle76967 a {color: #FFF;} .smaller-h3 h3 {font-size: 28px !important; } #press-releases .b2iLibToolsContainer select, #press-releases .b2iLibToolsContainer input {width: auto;} #press-releases #B2iLibSearchButton {margin-left: 5px;} .modal-dialog .dir-item-name, .modal-dialog .dir-item-title-text {line-height: 1.3em;} .amChartsPeriodSelectorButtonDiv {text-align: center;} .amChartsPeriodSelectorButtonDiv input[type="button"] {padding: 5px 10px; margin: 0 3px;} .team-layout3.dir-item-wrap {width: 23%;} .dir-item-photo-container img {min-width: 100%;} .dir-item-wrap_name-container, .team-layout3 .modal-content__header {background: #3A5DAE !important;} .dir-item-name {font-size: 15px;} .modal-content .dir-item-photo img {padding: 10px 10px 20px 10px;} .modal-content .dir-item-bio {font-size: 17px;} .modal-dialog, .modal-content {box-shadow: none !important;} .btn.ShowCaseLinkImage {color: #FFF; font-size: 16px; padding: 15px 35px; border: none;} #b2iSecForm select {width: auto;} #b2iSection23038 {padding-left: 0 !important; padding-right: 0 !important;} #b2iQuoteID10 .b2iClientQuote .b2iClientQuoteLabel {color: #333 !important;} .b2iPrimaryButton.b2iButton.b2iSecSearch.xxsmall {max-height: 30px; margin-left: 10px;} #b2iHistoricQuoteForm input {width: auto;} #b2iHistoricQuoteForm {padding-bottom: 30px;} .b2iSECtopSelectCell2 .select2 {width: auto !important; min-width: 250px;} .b2iSECtopSelect, .b2iSECtopSelecttd, .b2iSECtopSelect tr, .b2iSECtopTitleTable, .b2iSECtopTitleTable td, .b2iSECtopTitleTable tr, .b2iSECtopTitleTable th {border: none !important;} #b2iSecTop {margin-top: 20px;} .FilterLabel {margin-right: 5px; margin-left: 20px;} .b2iHeader.active, .b2iHeader:hover {background-color: #3A5DAE !important; color: #FFF; font-weight: 600;} .ir-content .document-report span, .ir-content .document-report {font-size: 19px;} .ir-content .document-report {padding-top: 20px;} .SECLayout16.SECItembutton-link a {background: #3A5DAE !important; font-size: 16px !important; font-weight: 600; padding: 15px 35px !important; box-shadow: none !important; } .b2iFinancialsHeader {line-height: 1.4em; margin-bottom: 20px;} .B2iFinancialsContainer, .B2iFinancialsContainer div, .B2iFinancialsContainer a {color: #333 !important;} .docDetails-col .DocItemTitle {margin-bottom: 5px;} #b2iEmailSignUp label {margin-left: 5px;} #b2iEmailSignUp input {border-radius: 0;} #b2iEmailList .b2iEmailFieldset {padding: 5px;} .ir-content .a-input-text, .ir-content .a-input-select, .ir-content .b2iFormRow input:not(.b2iEmailAlertCheckbox), .ir-content .b2iTextbox:not(.b2iEmailAlertCheckbox), .ir-content .InputDate, .ir-content #b2iSearchbox, .ir-content .b2iSelect {border-color: #3A5DAE; border-radius:0;} .ir-content {font-size: 19px;} .b2iPlugInHeadlinesDate {margin-top: 20px; margin-bottom: 2px !important;} .b2iLibToolsContainer .select2-selection__rendered {padding-left: 15px !important;} .ir-content .main-holder .site #content table.cart td.actions .input-text, .ir-content textarea, input[type="text"], .ir-content input[type="password"], .ir-content input[type="datetime"], .ir-content input[type="datetime-local"], .ir-content input[type="date"], .ir-content input[type="month"], .ir-content input[type="time"], .ir-content input[type="week"], .ir-content input[type="number"], .ir-content input[type="email"], .ir-content input[type="url"], .ir-content input[type="search"], .ir-content input[type="tel"], .ir-content input[type="color"], .ir-content .uneditable-input, .ir-content select {border: 1px solid #3A5DAE !important;} #b2iLibSearch input {margin-bottom: 10px; margin-top: 10px;} .ir-content button, .ir-content input[type="submit"], .ir-content input[type="button"], .ir-content input[type="reset"] {background-color: #3A5DAE;} .ir-content h3 {font-weight: 600; color: #031b4e; font-size: 36px; letter-spacing: -0.01em; margin-bottom: 20px; margin-top: 40px;} .ir-content, .ir-content a {color: #031b4e;} .current-menu-ancestor {background-color: rgba(0,0,0,0.3);} .inline-btns .btn {display: inline-block; margin-right: 4px;} .inline-btns br {display: none;} .page-id-8559 .ts-titlebar-main h1 {position: relative; z-index: 3;} .page-id-8559 .ts-titlebar-main .breadcrumb-wrapper {z-index: 2; position: relative;} .page-id-8559 .ts-titlebar-main:before {content: ''; position: absolute; z-index: 1; width: 100%; top: 0; left: 0; bottom: 0; background: #1B3C92; opacity: .5;} .stock-quote-section {background: #018A17; min-width: 100%; text-align: left; padding: 30px 0px 0px 0px;} .stock-quote-section .container {padding-left: 0 !important; padding-right: 0 !important;} .stock-quote-section .b2iQuote91data-title {color: #FFF; font-size:12px; } .stock-quote-section .b2iQuote91data, .stock-quote-section .data, .stock-quote-section .ChangeStyle {color: #FFF; font-size: 20px; font-weight: 700;} .ir-contacts-section {padding: 80px 0px 0px 0px !important;} .ir-contacts-section .ts-custom-heading {text-align: left;} .ir-contacts-data h3 {font-weight: 700; font-size: 20px; margin-top: 0; margin-bottom: 0; color: #031B4E;} .ir-contacts-data h4 {margin-top: 10px; color: #031B4E;} .ir-contacts-data {font-size: 18px; color: #212529; line-height: 1.3em;} .company-overview-section {padding: 80px 0px !important;} .company-overview-section h3 {font-weight: 600; font-size: 40px; letter-spacing: -0.02em; margin-bottom: 30px; margin-top: 0;} .company-overview-section p {color: #212529;} .company-overview-section .btn {margin-right: 5px; font-size: 15px;} .email-alerts-section h3 {color: #FFF; font-weight: 700; font-size: 40px; margin-top: 0;} .email-alerts-section {color: #FFF; padding: 60px 0px 20px 0px; background-size: cover; } .email-alerts-section p {font-size: 19px; letter-spacing: -0.02em; text-align: center;} .email-alerts-section .btn {color: #FFF; border-color: #FFF;} .email-signup-btn-col {text-align: right;} .latest-financial-results-section {padding: 80px 0px 40px 0px; background: #FFF!important;} .latest-1 .ts-cta3-content-wrapper {min-width: 100%;} .latest-1 .ts-custom-heading {text-align: left;} .latest-1 .flex.flex-third.filing-type {display: block !important; min-width: 100%; text-align: left;} .latest-1 .result-line {text-align: left; padding: 15px 0px !important;} .latest-1 a {color: #3A5DAE !important;} .latest-1 .filing-name {color: #031B4E; margin-top: 30px;} .latest-1 .qedate {color: #031B4E; margin-bottom: 10px;} .latest-1 .qedate span {display: inline-block; font-weight: 500; font-size: 12px;} .latest-1 .EndedSpan2 {margin-left: 5px;} .dots-img img {position: relative; z-index: 9;} .dots-img:after {content: ""; position: absolute; top: -54px; right: -40px; height: 136px; width: 132px; background: url(https://d1io3yog0oux5.cloudfront.net/_860e50159b1afe5949e7e2039c834240/lexariabioscience/files/theme/images/dots.svg) no-repeat center; background-size: 100%;} .dots-img-2 img {position: relative; z-index: 9;} .dots-img-2:after {content: ""; content: ""; position: absolute; bottom: -54px; left: -40px; height: 136px; width: 132px; background: url(https://d1io3yog0oux5.cloudfront.net/_860e50159b1afe5949e7e2039c834240/lexariabioscience/files/theme/images/dots.svg) no-repeat center; background-size: 100%;} .latest-annual-section .container {border-top: solid 1px #ddd; padding-top: 40px !important;} .latest-annual-section {background: #FFF !important; padding-bottom: 50px;} .latest-annual-section h3 {margin-top: 0; font-weight: 700;} .latest-annual-section h4 {margin-top: 10px;} .latest-annual-section h3, .latest-annual-section h4 {color: #031B4E !important;} .SECLayout22PDFItem-link.PDF-link a {color: #3A5DAE !important;} .SECLayout22PDF-formLinks {text-align: right;} .SECLayout22PDFItem-link.PDF-link {background: rgba(0, 0, 0, 0); display: inline-block; font-size: 16px; letter-spacing: normal; font-weight: 600; font-family: "Poppins", sans-serif; line-height: 1; margin-bottom: 5px; background: #FFF !important;border-radius: 0 !important; text-align: center; text-transform: none; white-space: normal; -moz-transition: background-color 0.2s ease, border-color 0.2s ease; -o-transition: background-color 0.2s ease, border-color 0.2s ease; -webkit-transition: background-color 0.2s ease, border-color 0.2s ease; transition: background-color 0.2s ease, border-color 0.2s ease; border: 2px solid #3A5DAE; color: #3A5DAE !important; margin: 0; padding: 15px 35px !important; border-radius: 0; text-decoration: none;} .news-right-btn {text-align: right;} .btn:hover {color: #FFF; background: #3A5DAE;} .btn {background: rgba(0, 0, 0, 0); display: inline-block; font-size: 16px; letter-spacing: normal; font-weight: 600; font-family: "Poppins", sans-serif; line-height: 1; margin-bottom: 5px; text-align: center; text-transform: none; white-space: normal; -moz-transition: background-color 0.2s ease, border-color 0.2s ease; -o-transition: background-color 0.2s ease, border-color 0.2s ease; -webkit-transition: background-color 0.2s ease, border-color 0.2s ease; transition: background-color 0.2s ease, border-color 0.2s ease; border: 2px solid #3A5DAE; color: #3A5DAE; margin: 0; padding: 15px 35px; border-radius: 0; text-decoration: none;} #b2iPlugInHeadLine {padding-left: 0;} #b2iPlugInHeadLine li {list-style: none;} .b2iPlugInHeadlinesDate {margin-bottom: 10px;} .news-2 .b2iLibraryHeadlineLink {font-size: 18px !important; font-weight:400; text-decoration: underline;} .news-2 .b2iPlugInHeadlinesItem {margin-bottom:25px;} .b2iHeadLinesDateCell, .b2iPlugInHeadlinesDate {font-size:12px; text-transform: none; font-weight: 400; color: #031B4E;} .news-2 #b2iLibNav, .news-1 #b2iLibNav {display: none;} .full-row-grey {background: #EBEFF7; padding: 60px 0px; } .full-row-grey .vc_row.container { padding: 30px 30px 30px 30px !important; background: #FFF; } .full-row-grey h3 {font-weight: 700; letter-spacing: -0.01em; font-size: 20px;} .ts-titlebar-main h1 {font-family: 'Poppins' !important; text-transform: none !important; letter-spacing: -0.02em !important;} div.investor-menu li.current-menu-item {background-color: rgba(0,0,0,0.3);} .b2iPressContainer table, .b2iPressContainer tr, .b2iPressContainer td {border: none;} .b2iHeadLinesHeadlineCell a {font-weight: 400; text-decoration: underline; font-size: 26px; line-height: 1.3em;} div.investor-menu {background-color: #3A5DAE !important;} div.investor-menu a {font-size: 13px; font-weight: 700; line-height: 1.4em; letter-spacing: 0;} div.investor-menu li {display: inline-block; float: none; position: relative; text-align: left;} /* Basic styles for the menu container */ div.investor-menu { background-color: #333; position: relative; } /* Style for the main menu items */ div.investor-menu ul.menu { list-style-type: none; margin: 0; padding: 0; display: flex; flex-direction: row; /* Align items horizontally */ } /* Style for individual menu items */ div.investor-menu ul.menu > li { position: relative; } /* Style for links */ div.investor-menu ul.menu > li > a { display: block; color: white; text-align: center; padding: 14px 16px; text-decoration: none; } /* Change color on hover */ div.investor-menu ul.menu > li > a:hover { background-color: #111; } /* Style for the dropdown */ div.investor-menu ul.menu li ul.sub-menu { display: none; position: absolute; background-color: #333; min-width: 160px; z-index: 999; list-style-type: none; margin: 0; padding: 0; } /* Style for dropdown links */ div.investor-menu ul.menu li ul.sub-menu li a { padding: 12px 16px; text-decoration: none; display: block; text-align: left; color: white; } /* Show the dropdown on hover */ div.investor-menu ul.menu li:hover ul.sub-menu { display: block; } /* Hamburger menu styles */ div.investor-menu .hamburger { display: none; font-size: 30px; color: white; padding: 14px 16px; cursor: pointer; } /* Media query for screens 1000px or smaller */ @media screen and (max-width: 1000px) { /* Stack the menu items vertically */ div.investor-menu ul.menu { flex-direction: column; display: none; /* Hide menu by default */ width: 100%; } /* Show the hamburger icon */ div.investor-menu .hamburger { display: block; } /* Show menu when active */ div.investor-menu ul.menu.active { display: flex; } /* Style for links in vertical mode */ div.investor-menu ul.menu > li > a { text-align: left; padding: 12px 16px; } /* Dropdowns in vertical mode */ div.investor-menu ul.menu li ul.sub-menu { position: relative; } } </style> <!-- end Simple Custom CSS and JS --> <style> ul.cnss-social-icon li.cn-fa-icon a{background-color:#3a5dae!important;} ul.cnss-social-icon li.cn-fa-icon a:hover{background-color:#264899!important;color:#ffffff!important;} </style><meta name="generator" content="Site Kit by Google 1.146.0" /><!-- Inline CSS Start --><!-- Inline CSS End --><meta name="generator" content="Powered by WPBakery Page Builder - drag and drop page builder for WordPress."/> <!-- Google Tag Manager snippet added by Site Kit --> <script> /* <![CDATA[ */ ( function( w, d, s, l, i ) { w[l] = w[l] || []; w[l].push( {'gtm.start': new Date().getTime(), event: 'gtm.js'} ); var f = d.getElementsByTagName( s )[0], j = d.createElement( s ), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src = 'https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore( j, f ); } )( window, document, 'script', 'dataLayer', 'GTM-KNPGWSZ' ); /* ]]> */ </script> <!-- End Google Tag Manager snippet added by Site Kit --> <meta name="generator" content="Powered by Slider Revolution 6.5.15 - responsive, Mobile-Friendly Slider Plugin for WordPress with comfortable drag and drop interface." /> <link rel="icon" href="https://lexariabioscience.com/wp-content/uploads/2022/06/cropped-Lexaria_Bioscience_Logo_Square_SocialMedia_A-32x32.png" sizes="32x32" /> <link rel="icon" href="https://lexariabioscience.com/wp-content/uploads/2022/06/cropped-Lexaria_Bioscience_Logo_Square_SocialMedia_A-192x192.png" sizes="192x192" /> <link rel="apple-touch-icon" href="https://lexariabioscience.com/wp-content/uploads/2022/06/cropped-Lexaria_Bioscience_Logo_Square_SocialMedia_A-180x180.png" /> <meta name="msapplication-TileImage" content="https://lexariabioscience.com/wp-content/uploads/2022/06/cropped-Lexaria_Bioscience_Logo_Square_SocialMedia_A-270x270.png" /> <script>function setREVStartSize(e){ //window.requestAnimationFrame(function() { window.RSIW = window.RSIW===undefined ? window.innerWidth : window.RSIW; window.RSIH = window.RSIH===undefined ? window.innerHeight : window.RSIH; try { var pw = document.getElementById(e.c).parentNode.offsetWidth, newh; pw = pw===0 || isNaN(pw) ? window.RSIW : pw; e.tabw = e.tabw===undefined ? 0 : parseInt(e.tabw); e.thumbw = e.thumbw===undefined ? 0 : parseInt(e.thumbw); e.tabh = e.tabh===undefined ? 0 : parseInt(e.tabh); e.thumbh = e.thumbh===undefined ? 0 : parseInt(e.thumbh); e.tabhide = e.tabhide===undefined ? 0 : parseInt(e.tabhide); e.thumbhide = e.thumbhide===undefined ? 0 : parseInt(e.thumbhide); e.mh = e.mh===undefined || e.mh=="" || e.mh==="auto" ? 0 : parseInt(e.mh,0); if(e.layout==="fullscreen" || e.l==="fullscreen") newh = Math.max(e.mh,window.RSIH); else{ e.gw = Array.isArray(e.gw) ? e.gw : [e.gw]; for (var i in e.rl) if (e.gw[i]===undefined || e.gw[i]===0) e.gw[i] = e.gw[i-1]; e.gh = e.el===undefined || e.el==="" || (Array.isArray(e.el) && e.el.length==0)? e.gh : e.el; e.gh = Array.isArray(e.gh) ? e.gh : [e.gh]; for (var i in e.rl) if (e.gh[i]===undefined || e.gh[i]===0) e.gh[i] = e.gh[i-1]; var nl = new Array(e.rl.length), ix = 0, sl; e.tabw = e.tabhide>=pw ? 0 : e.tabw; e.thumbw = e.thumbhide>=pw ? 0 : e.thumbw; e.tabh = e.tabhide>=pw ? 0 : e.tabh; e.thumbh = e.thumbhide>=pw ? 0 : e.thumbh; for (var i in e.rl) nl[i] = e.rl[i]<window.RSIW ? 0 : e.rl[i]; sl = nl[0]; for (var i in nl) if (sl>nl[i] && nl[i]>0) { sl = nl[i]; ix=i;} var m = pw>(e.gw[ix]+e.tabw+e.thumbw) ? 1 : (pw-(e.tabw+e.thumbw)) / (e.gw[ix]); newh = (e.gh[ix] * m) + (e.tabh + e.thumbh); } var el = document.getElementById(e.c); if (el!==null && el) el.style.height = newh+"px"; el = document.getElementById(e.c+"_wrapper"); if (el!==null && el) { el.style.height = newh+"px"; el.style.display = "block"; } } catch(e){ console.log("Failure at Presize of Slider:" + e) } //}); };</script> <noscript><style> .wpb_animate_when_almost_visible { opacity: 1; }</style></noscript></head> <body class="archive date ts-headerstyle-infostack themestek-wide themestek-sidebar-true themestek-sidebar-right wpb-js-composer js-comp-ver-7.7.2 vc_responsive"> <!-- Google Tag Manager (noscript) snippet added by Site Kit --> <noscript> <iframe src="https://www.googletagmanager.com/ns.html?id=GTM-KNPGWSZ" height="0" width="0" style="display:none;visibility:hidden"></iframe> </noscript> <!-- End Google Tag Manager (noscript) snippet added by Site Kit --> <div id="ts-home"></div> <div class="main-holder"> <div id="page" class="hfeed site"> <header id="masthead" class=" ts-header-style-infostack themestek-main-menu-total-5"> <div class="ts-header-block ts-mmenu-active-color-custom ts-dmenu-active-color-skin ts-dmenu-sep-grey"> <div id="site-header" class="site-header ts-bgcolor-transparent ts-sticky-bgcolor-white ts-mmmenu-override-yes ts-above-content-yes"> <div class="site-header-main ts-table"> <div class="ts-header-top-wrapper container"> <div class="site-branding"> <div class="headerlogo themestek-logotype-image ts-stickylogo-no"><span class="site-title"><span class="logo-link-text">Lexaria Bioscience - </span><a class="home-link" href="https://lexariabioscience.com/" title="Lexaria Bioscience" rel="home"><span class="ts-sc-logo ts-sc-logo-type-image"><img class="themestek-logo-img standardlogo" alt="Lexaria Bioscience" src=" http://lexariabioscience.com/wp-content/uploads/2022/03/Lexaria_Bioscience_Logo_Dark_WEB.png"></span></a></span><h2 class="site-description"></h2></div> </div><!-- .site-branding --> <div class="ts-infostack-right-content"> <div class="info-widget"> <div class="info-widget-inner"> </div> </div> <div class="info-widget"> <div class="info-widget-inner"> </div> </div> <div class="info-widget"> <div class="info-widget-inner"> NASDAQ:LEXX; NASDAQ WARRANT:LEXXW </div> </div> </div> </div><!-- .ts-header-top-wrapper --> <div id="ts-stickable-header-w" class="ts-stickable-header-w ts-bgcolor-transparent" style="height:60px"> <div id="site-header-menu" class="site-header-menu container"> <div class="site-header-menu-inner ts-stickable-header ts-header-menu-bg-color-skincolor ts-bgcolor-skincolor ts-sticky-bgcolor-darkgrey"> <div class="site-header-menu-middle ts-header-menu-bg-color-skincolor ts-bgcolor-skincolor ts-sticky-bgcolor-darkgrey"> <div class="container "> <div> <nav id="site-navigation" class="main-navigation" aria-label="Primary Menu" data-sticky-height="90"> <button id="menu-toggle" class="menu-toggle"> <span class="ts-hide">Toggle menu</span><i class="ts-labtechco-icon-bars"></i> </button> <div class="nav-menu"><ul id="menu-main-menu" class="nav-menu"><li id="menu-item-7921" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-home menu-item-7921"><a href="https://lexariabioscience.com/">Home</a></li> <li id="menu-item-7917" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-7917"><a href="https://lexariabioscience.com/about-lexaria/">About</a> <ul class="sub-menu"> <li id="menu-item-7918" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7918"><a href="https://lexariabioscience.com/about-lexaria/#management">Management</a></li> <li id="menu-item-7948" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7948"><a href="https://lexariabioscience.com/about-lexaria/#board-of-directors">Board of Directors</a></li> <li id="menu-item-9125" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-9125"><a href="https://lexariabioscience.com/about-lexaria/#Scientific-Advisory-Board">Scientific Advisory Board</a></li> <li id="menu-item-7949" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7949"><a href="https://lexariabioscience.com/about-lexaria/#advisors-and-consultants">Advisors & Consultants</a></li> </ul> </li> <li id="menu-item-7981" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-7981"><a href="https://lexariabioscience.com/technology/">Technology</a> <ul class="sub-menu"> <li id="menu-item-7987" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-7987"><a href="https://lexariabioscience.com/technology/">Overview</a></li> <li id="menu-item-7989" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7989"><a href="https://lexariabioscience.com/technology/#commercial-applications">Commercial Applications</a></li> <li id="menu-item-7982" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-7982"><a href="https://lexariabioscience.com/research/">Research</a></li> <li id="menu-item-8016" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-8016"><a href="https://lexariabioscience.com/patent-portfolio/">Patent Portfolio</a></li> </ul> </li> <li id="menu-item-8020" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-8020"><a href="https://lexariabioscience.com/licensing-opportunities/">Licensing Opportunities</a></li> <li id="menu-item-8025" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-8025"><a href="https://lexariabioscience.com/investors/">Investors</a></li> </ul></div> </nav><!-- .main-navigation --> </div> <div class="ts-phone"> <div class="ts-header-text-area ts-header-button-w"> <div class="ts-vc_btn3-container ts-vc_btn3-inline"><a class="ts-vc_general ts-vc_btn3 ts-vc_btn3-size-md ts-vc_btn3-shape-square ts-vc_btn3-style-flat ts-vc_btn3-weight-yes ts-vc_btn3-color-skincolor" href="https://lexariabioscience.com/contact/" title="">Contact</a></div></div> </div> </div> </div> </div> </div><!-- .site-header-menu --> </div> </div><!-- .site-header-main --> </div> <div class="ts-titlebar-wrapper ts-bg ts-bgcolor-transparent ts-titlebar-align-left ts-textcolor-white ts-bgimage-yes"> <div class="ts-titlebar-wrapper-bg-layer ts-bg-layer"></div> <div class="ts-titlebar entry-header"> <div class="ts-titlebar-inner-wrapper"> <div class="ts-titlebar-main"> <div class="container"> <div class="ts-titlebar-main-inner"> <div class="entry-title-wrapper"><div class="container"><h1 class="entry-title"> Monthly Archives: <span>December 2021</span></h1></div></div><div class="breadcrumb-wrapper"><div class="container"><div class="breadcrumb-wrapper-inner"><!-- Breadcrumb NavXT output --><span><a title="Go to Lexaria Bioscience." href="https://lexariabioscience.com" class="home"><i class="fa fa-home"></i><span class="hide">Lexaria Bioscience</span></a></span> <span class="ts-bread-sep"> → </span><span><a title="Go to Blog Large Image." href="https://lexariabioscience.com/blog-large-image/" class="post-root post post-post"><span>Blog Large Image</span></a></span><span class="ts-bread-sep"> → </span><span><a title="Go to the 2021 archives." href="https://lexariabioscience.com/2021/" class="archive date-year"><span>2021</span></a></span><span class="ts-bread-sep"> → </span><span><span class="archive date-month current-item">December</span></span></div></div></div> </div> </div> </div><!-- .ts-titlebar-main --> </div><!-- .ts-titlebar-inner-wrapper --> </div><!-- .ts-titlebar --> </div><!-- .ts-titlebar-wrapper --> </div> </header><!-- .site-header --> <div id="content-wrapper" class="site-content-wrapper"> <div id="content" class="site-content container"> <div id="content-inner" class="site-content-inner row multi-columns-row"> <div id="primary" class="content-area col-md-9 col-lg-9 col-xs-12"> <main id="main" class="site-main"> <article id="post-8916" class="ts-no-featured-content themestek-box-blog-classic post-8916 post type-post status-publish format-standard hentry category-press-releases" > <div class="ts-blog-classic-featured-wrapper"> <div class="ts-blog-classic-datebox-overlay"> <div class="ts-blog-classic-dbox-date">29</div> <div class="ts-blog-classic-dbox-month">Dec</div> </div> </div> <div class="ts-blog-classic-box-content "> <!-- Blog classic meta Start --> <div class="ts-featured-meta-wrapper ts-featured-overlay"> <div class="ts-blog-post-date"> <span class="ts-meta-line"><span class="screen-reader-text ts-hide">Date </span> <i class="ts-labtechco-icon-clock"></i> <a href="https://lexariabioscience.com/2021/12/29/lexaria-receives-independent-review-board-approval-for-dehydratech-cbd-human-clinical-study-hyper-h21-4/">December 29, 2021</a></span> </div> <div class="ts-blog-post-cat ts-blog-post-cat-above-title"> <span class="ts-meta-line cat-links"><span class="screen-reader-text ts-hide">Categories </span> <i class="ts-labtechco-icon-category"></i> <a href="https://lexariabioscience.com/category/press-releases/">Press Releases</a></span> </div> <div class="themestek-box-title"><h4><a href="https://lexariabioscience.com/2021/12/29/lexaria-receives-independent-review-board-approval-for-dehydratech-cbd-human-clinical-study-hyper-h21-4/">Lexaria Receives Independent Review Board Approval For DehydraTECH-CBD Human Clinical Study HYPER-H21-4</a></h4></div> </div> <!-- Blog classic meta End --> <div class="entry-content"> <div class="themestek-box-desc-text"><div class="b2iNewsItemBodyDiv"><p>• <i><strong>Dosing is expected to begin by April, 2022</strong></i></p><p><strong>KELOWNA, BC / December 29, 2021 / </strong>Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "<strong>Company</strong>" or "<strong>Lexaria</strong>"), a global innovator in drug delivery platforms, is pleased to report that Independent Review Board ("IRB") approval has been received ahead of schedule for its upcoming DehydraTECH-CBD human hypertension study HYPER-H21-4.</p><p>This study should "de-risk" outcomes prior to Lexaria's planned entry into regulatory pathways for the use of DehydraTECH-CBD to treat hypertension and perhaps other forms of cardiovascular disease. This study is entirely funded through the Company's existing cash resources and is not subject to any financing requirement. Dosing is tentatively scheduled to begin by April, 2022.</p><p>HYPER-H21-4 is expected to consist of 60 volunteers between the ages of 45-70 using three 150 mg doses of DehydraTECH-CBD, every day for the 6-week duration of the study. The study will use a double blinded, randomized cross-over design, and a placebo control. Some volunteers will already be using leading standard of care hypertension drugs such as ACE inhibitors with or without diuretics which will help evaluate the efficacy of DehydraTECH-CBD with and without other hypertension treatments. The extended duration of the study will allow Lexaria to gather critical data monitoring of DehydraTECH-CBD over time and will evaluate the potential for longer term health benefits.</p><p>HYPER-H21-4 is more comprehensive than any work previously undertaken by Lexaria and many types of analysis will be performed including 24-hour ambulatory blood pressure (the primary outcome); arterial stiffness and autonomic balance; brain structure and function through brain magnetic resonance imaging ("MRI"); blood biomarkers (including lipids such as cholesterol and more); renal, hepatic, sleep quality / daytime sleepiness / sleep disorders; actigraphy, geriatric depression scale, perceived stress, and Beck anxiety inventory. The wide range of data collection could provide additional insights into the long-term health benefits of DehydraTECH-CBD that might otherwise remain undetected.</p><p><strong>Hypertension Markets</strong></p><p>The hypertension market is valued at <a href="https://pr.report/h0WEHDIU">$28 billion per year</a> and is expected to continue growing as one of the world's top health problems and as a subset of the larger heart disease market. Geographically, some of the highest rates of growth are expected in more recently industrialized nations such as China and India. <a href="https://pr.report/-bhNOwqo">Over 1.1 billion people</a> worldwide suffer from hypertension.</p><p>Fewer than <a href="https://pr.report/ZnuPghcv">1 person in 4 with hypertension</a> have successfully controlled their blood pressure through medications, meaning the potential market for hypertension drugs is much larger than $28 billion per year if an affordable drug was available with few or no side effects. Lexaria believes that its DehydraTECH-CBD may introduce a more tolerable anti-hypertensive treatment option that may be used alone or in combination with other medications, to reduce BP with fewer discouraging and unwanted side effects. Lexaria would seek to satisfy this currently unmet demand and in doing so could expand the overall hypertension market.</p><p>"Among persons 50 years of age or older, isolated systolic hypertension is the most common form of hypertension, and systolic blood pressure becomes more important than diastolic blood pressure as an independent risk predictor for coronary events, stroke, heart failure, and end-stage renal disease (ESRD). The Global Burden of Disease Study identified elevated blood pressure as the leading risk factor, among 67 studied, for death and disability-adjusted <a href="https://pr.report/Mj3QZ7m2">life-years lost during 2010."</a></p><p>Drugs focused on blood pressure and related conditions are some of the <a href="https://pr.report/Qq0GXDME">highest selling drugs</a> in the world. Lipitor, used to treat high cholesterol and reduce the risk of heart disease, has generated $94.7 billion in revenue from 1992 until 2017. Plavix, used to prevent heart attack and stroke, has sold $46.5 billion from 1992 until 2017. There are <a href="https://pr.report/wvJmf3P5">several hypertension drugs</a> that each generate $1 billion per year or more in revenue.</p><p><strong>About Lexaria Bioscience Corp.</strong></p><p>Lexaria Bioscience Corp.'s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 23 patents granted and over 50 patents pending worldwide. For more information, please visit <a href="https://pr.report/3OUWMKYL">www.lexariabioscience.com</a>.</p><p><strong>CAUTION REGARDING FORWARD-LOOKING STATEMENTS</strong></p><p>This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.</p><p><strong>INVESTOR CONTACT:</strong><br><strong>George Jurcic - Head of Investor Relations</strong><br><a href="/cdn-cgi/l/email-protection#2d445f6d4148554c5f444c4f44425e4e4448434e48034e4240"><span class="__cf_email__" data-cfemail="91f8e3d1fdf4e9f0e3f8f0f3f8fee2f2f8f4fff2f4bff2fefc">[email protected]</span></a><br>Phone: 250-765-6424, ext 202</p><p><strong>SOURCE:</strong> Lexaria Bioscience Corp.</p><br><br>View source version on accesswire.com: <br><a href='https://www.accesswire.com/679972/Lexaria-Receives-Independent-Review-Board-Approval-For-DehydraTECH-CBD-Human-Clinical-Study-HYPER-H21-4'>https://www.accesswire.com/679972/Lexaria-Receives-Independent-Review-Board-Approval-For-DehydraTECH-CBD-Human-Clinical-Study-HYPER-H21-4</a><br><br><img src='https://www.accesswire.com/img.ashx?id=679972' /></div></div> <div class="themestek-blog-classic-footer-readmore"> <div class="themestek-blogbox-footer-left"><a href="https://lexariabioscience.com/2021/12/29/lexaria-receives-independent-review-board-approval-for-dehydratech-cbd-human-clinical-study-hyper-h21-4/">Read More</a></div> </div> <div class="ts-footer-meta-wrapper"> <span class="ts-footer-meta-line-w ts-footer-meta-line-comments"> <a href="https://lexariabioscience.com/2021/12/29/lexaria-receives-independent-review-board-approval-for-dehydratech-cbd-human-clinical-study-hyper-h21-4/"> <i class="ts-labtechco-icon-comment-1"></i> <span class="comments"> 0 Comments </span> </a> </span> <span class="ts-footer-meta-line-w ts-footer-meta-line-author"> <span class="author vcard"> <span class="screen-reader-text ts-hide">Author </span> <a class="url fn n" href="https://lexariabioscience.com/author/mmcdonald/"><i class="ts-labtechco-icon-user"></i> mmcdonald</a> </span> </span> </div> </div><!-- .entry-content --> </div><!-- .ts-blog-classic-box-content --> </article><!-- #post-## --> <article id="post-8917" class="ts-no-featured-content themestek-box-blog-classic post-8917 post type-post status-publish format-standard hentry category-press-releases" > <div class="ts-blog-classic-featured-wrapper"> <div class="ts-blog-classic-datebox-overlay"> <div class="ts-blog-classic-dbox-date">16</div> <div class="ts-blog-classic-dbox-month">Dec</div> </div> </div> <div class="ts-blog-classic-box-content "> <!-- Blog classic meta Start --> <div class="ts-featured-meta-wrapper ts-featured-overlay"> <div class="ts-blog-post-date"> <span class="ts-meta-line"><span class="screen-reader-text ts-hide">Date </span> <i class="ts-labtechco-icon-clock"></i> <a href="https://lexariabioscience.com/2021/12/16/lexaria-enters-one-year-media-outreach-agreement-with-srax-inc/">December 16, 2021</a></span> </div> <div class="ts-blog-post-cat ts-blog-post-cat-above-title"> <span class="ts-meta-line cat-links"><span class="screen-reader-text ts-hide">Categories </span> <i class="ts-labtechco-icon-category"></i> <a href="https://lexariabioscience.com/category/press-releases/">Press Releases</a></span> </div> <div class="themestek-box-title"><h4><a href="https://lexariabioscience.com/2021/12/16/lexaria-enters-one-year-media-outreach-agreement-with-srax-inc/">Lexaria Enters One-Year Media Outreach Agreement with SRAX, Inc.</a></h4></div> </div> <!-- Blog classic meta End --> <div class="entry-content"> <div class="themestek-box-desc-text"><div class="b2iNewsItemBodyDiv"><p><strong>KELOWNA, BC / December 16, 2021</strong> / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "<strong>Company</strong>" or "<strong>Lexaria</strong>"), a global innovator in drug delivery platforms announces that it has entered into an advertising and media agreement (the "<strong>Contract</strong>") for media buys and digital marketing with SRAX, Inc. ("<strong>SRAX</strong>").</p><p>"Lexaria is pleased to be working with SRAX to inform and engage a broad investor community in this significant, year-long media outreach campaign," said Chris Bunka, CEO of Lexaria Bioscience. "Lexaria has made tremendous progress during 2021 and we expect even more significant advancement in 2022 and are pursuing the broadest possible investor involvement to ensure that Lexaria's achievements are communicated to all investors."</p><p>Lexaria is planning for 2022 to be its busiest year ever, with major studies and events already announced that include:</p><ul><li>a six-week human clinical hypertension study to evaluate DehydraTECH-CBD for possible relief of hypertension;</li><li>an industry-leading oral nicotine human study including both subjective evaluation and objective blood measurements expected to demonstrate the superiority of DehydraTECH-nicotine compared to leading industry products;</li><li>a program of animal studies designed to evaluate DehydraTECH-CBD for seizure relief and comparison against the only existing FDA-approved CBD medication currently in use for treatment of certain seizure disorders; and</li><li>our expectation of completing a pre-IND meeting with the FDA, and subsequently filing an IND application, for registered clinical trial testing of DehydraTECH-CBD for hypertension.</li></ul><p>Along with those major studies Lexaria will also be conducting a number of pharmacokinetic studies designed to provide potential early-stage indications of enhancing delivery characteristics of various drugs for potential future use. In aggregate, the quantity of work to be performed demands the maximum visibility possible to the investor community and therefore should be maximized with a sustained and intelligent marketing campaign.</p><p>Pursuant to the Contract, SRAX will act as the agent for Lexaria and will engage and manage media companies to create advertising materials and distribute them on internet platforms and manage the flow of such media distributions (the "<strong>Services</strong>"). SRAX will employ leading-edge analytical algorithms to maximize engagement. As consideration for the Services, Lexaria will issue SRAX an aggregate 224,299 restricted common shares from its authorized share capital (the "<strong>Shares</strong>") at a deemed price of $5.35 per share for an aggregate value of $1,200,000.</p><p>The Shares have not been registered under the Securities Act of 1933, as amended (the "<strong>Securities Act</strong>") or any state securities laws. The issuance of the Shares will be in reliance on the exemptions from registration provided by Section 4(a)(2) under the Securities Act.</p><p><strong>About SRAX</strong></p><p>SRAX (SRAX) is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors' behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information on SRAX, visit <a href="https://pr.report/zvj2K6eL">srax.com</a> and <a href="https://pr.report/91pzoPOB">mysequire.com</a>.</p><p><strong>About Lexaria Bioscience Corp.</strong></p><p>Lexaria Bioscience Corp.'s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 23 patents granted and over 50 patents pending worldwide. For more information, please visit <a href="https://pr.report/DPadtS87">www.lexariabioscience.com</a>.</p><p><strong>CAUTION REGARDING FORWARD-LOOKING STATEMENTS</strong></p><p>This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.</p><p><strong>INVESTOR CONTACT:</strong></p><p><strong>George Jurcic - Head of Investor Relations</strong><br><a href="/cdn-cgi/l/email-protection#8ce5fecce0e9f4edfee5edeee5e3ffefe5e9e2efe9a2efe3e1"><span class="__cf_email__" data-cfemail="ea8398aa868f928b98838b8883859989838f84898fc4898587">[email protected]</span></a><br>Phone: 250-765-6424, ext 202</p><p><strong>SOURCE</strong>: Lexaria Bioscience Corp.</p><br><br>View source version on accesswire.com: <br><a href='https://www.accesswire.com/678184/Lexaria-Enters-One-Year-Media-Outreach-Agreement-with-SRAX-Inc'>https://www.accesswire.com/678184/Lexaria-Enters-One-Year-Media-Outreach-Agreement-with-SRAX-Inc</a><br><br><img src='https://www.accesswire.com/img.ashx?id=678184' /></div></div> <div class="themestek-blog-classic-footer-readmore"> <div class="themestek-blogbox-footer-left"><a href="https://lexariabioscience.com/2021/12/16/lexaria-enters-one-year-media-outreach-agreement-with-srax-inc/">Read More</a></div> </div> <div class="ts-footer-meta-wrapper"> <span class="ts-footer-meta-line-w ts-footer-meta-line-comments"> <a href="https://lexariabioscience.com/2021/12/16/lexaria-enters-one-year-media-outreach-agreement-with-srax-inc/"> <i class="ts-labtechco-icon-comment-1"></i> <span class="comments"> 0 Comments </span> </a> </span> <span class="ts-footer-meta-line-w ts-footer-meta-line-author"> <span class="author vcard"> <span class="screen-reader-text ts-hide">Author </span> <a class="url fn n" href="https://lexariabioscience.com/author/mmcdonald/"><i class="ts-labtechco-icon-user"></i> mmcdonald</a> </span> </span> </div> </div><!-- .entry-content --> </div><!-- .ts-blog-classic-box-content --> </article><!-- #post-## --> <article id="post-8918" class="ts-no-featured-content themestek-box-blog-classic post-8918 post type-post status-publish format-standard hentry category-press-releases" > <div class="ts-blog-classic-featured-wrapper"> <div class="ts-blog-classic-datebox-overlay"> <div class="ts-blog-classic-dbox-date">14</div> <div class="ts-blog-classic-dbox-month">Dec</div> </div> </div> <div class="ts-blog-classic-box-content "> <!-- Blog classic meta Start --> <div class="ts-featured-meta-wrapper ts-featured-overlay"> <div class="ts-blog-post-date"> <span class="ts-meta-line"><span class="screen-reader-text ts-hide">Date </span> <i class="ts-labtechco-icon-clock"></i> <a href="https://lexariabioscience.com/2021/12/14/lexarias-clinical-hypertension-study-hyper-h21-3-nears-completion/">December 14, 2021</a></span> </div> <div class="ts-blog-post-cat ts-blog-post-cat-above-title"> <span class="ts-meta-line cat-links"><span class="screen-reader-text ts-hide">Categories </span> <i class="ts-labtechco-icon-category"></i> <a href="https://lexariabioscience.com/category/press-releases/">Press Releases</a></span> </div> <div class="themestek-box-title"><h4><a href="https://lexariabioscience.com/2021/12/14/lexarias-clinical-hypertension-study-hyper-h21-3-nears-completion/">Lexaria’s Clinical Hypertension Study HYPER-H21-3 Nears Completion</a></h4></div> </div> <!-- Blog classic meta End --> <div class="entry-content"> <div class="themestek-box-desc-text"><div class="b2iNewsItemBodyDiv"><p><strong>KELOWNA, BC / December 14, 2021 /</strong> Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that its human clinical study HYPER-H21-3 is expected to complete all dosing and sample collection this week.</p><p>Formal hospital and ethics board approvals for human clinical study HYPER-H21-3 had been received in March. Study HYPER-H21-3 used a placebo-controlled and blinded design, with administration of a single 300mg dose of a specific DehydraTECH 2.0 CBD formulation compared to placebo in a target group of sixteen enrolled volunteers. This "Stress Test" study was undertaken to examine the effects of DehydraTECH-CBD upon acute pulmonary hypertension. Blood samples collected from this study will be subjected to analysis and the blood pressure results are expected to be reported soon.</p><p>Exposure to acute reductions in oxygen tension (i.e., hypoxia) causes rapid hypoxic pulmonary vasoconstriction (HPV) and, as a consequence of this HPV response, pulmonary arterial pressure increases. If this increase in pressure becomes too high, as is the case in many cardiac pathologies, an excess of fluid in the lungs can occur that causes difficulty with breathing.</p><p>The extent to which CBD may act as a novel treatment for HPV, and potentially as an alternative treatment for pulmonary hypertension, is unknown. Thus, the primary objective of this study is to evaluate the effect of DehydraTECH-CBD on pulmonary vascular function in normotensive individuals exposed to hypoxia. The magnitude of HPV, blood pressure, heart rate, blood samples and pulmonary gas exchange data is being collected and analysis is ongoing.</p><p>Results from study HYPER-H21-3 are expected to add to Lexaria's growing body of evidence for the effectiveness of DehydraTECH-CBD against hypertension, and will be submitted to regulators such as the FDA, as the Company pursues its planned <a href="https://pr.report/WhXu3nRN">investigational new drug research program</a>. Lexaria offers its gratitude to the teams of experts conducting its series of three human clinical studies through 2021 overwhelmingly on schedule and on budget particularly during the past year when challenges from the COVID-19 epidemic were pronounced.</p><p><strong>About Lexaria Bioscience Corp.</strong></p><p>Lexaria Bioscience Corp.'s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 23 patents granted and over 50 patents pending worldwide. For more information, please visit <a href="https://pr.report/3kHUZ-cB">www.lexariabioscience.com</a>.</p><p><strong>CAUTION REGARDING FORWARD-LOOKING STATEMENTS</strong></p><p>This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.</p><p><strong>INVESTOR CONTACT:</strong></p><p><strong>George Jurcic - Head of Investor Relations</strong><br><a href="/cdn-cgi/l/email-protection#721b00321e170a13001b13101b1d01111b171c11175c111d1f"><span class="__cf_email__" data-cfemail="4f263d0f232a372e3d262e2d26203c2c262a212c2a612c2022">[email protected]</span></a><br>Phone: 250-765-6424, ext 202</p><p><strong>SOURCE:</strong> Lexaria Bioscience Corp.</p><br><br>View source version on accesswire.com: <br><a href='https://www.accesswire.com/677626/Lexarias-Clinical-Hypertension-Study-HYPER-H21-3-Nears-Completion'>https://www.accesswire.com/677626/Lexarias-Clinical-Hypertension-Study-HYPER-H21-3-Nears-Completion</a><br><br><img src='https://www.accesswire.com/img.ashx?id=677626' /></div></div> <div class="themestek-blog-classic-footer-readmore"> <div class="themestek-blogbox-footer-left"><a href="https://lexariabioscience.com/2021/12/14/lexarias-clinical-hypertension-study-hyper-h21-3-nears-completion/">Read More</a></div> </div> <div class="ts-footer-meta-wrapper"> <span class="ts-footer-meta-line-w ts-footer-meta-line-comments"> <a href="https://lexariabioscience.com/2021/12/14/lexarias-clinical-hypertension-study-hyper-h21-3-nears-completion/"> <i class="ts-labtechco-icon-comment-1"></i> <span class="comments"> 0 Comments </span> </a> </span> <span class="ts-footer-meta-line-w ts-footer-meta-line-author"> <span class="author vcard"> <span class="screen-reader-text ts-hide">Author </span> <a class="url fn n" href="https://lexariabioscience.com/author/mmcdonald/"><i class="ts-labtechco-icon-user"></i> mmcdonald</a> </span> </span> </div> </div><!-- .entry-content --> </div><!-- .ts-blog-classic-box-content --> </article><!-- #post-## --> <article id="post-8919" class="ts-no-featured-content themestek-box-blog-classic post-8919 post type-post status-publish format-standard hentry category-press-releases" > <div class="ts-blog-classic-featured-wrapper"> <div class="ts-blog-classic-datebox-overlay"> <div class="ts-blog-classic-dbox-date">08</div> <div class="ts-blog-classic-dbox-month">Dec</div> </div> </div> <div class="ts-blog-classic-box-content "> <!-- Blog classic meta Start --> <div class="ts-featured-meta-wrapper ts-featured-overlay"> <div class="ts-blog-post-date"> <span class="ts-meta-line"><span class="screen-reader-text ts-hide">Date </span> <i class="ts-labtechco-icon-clock"></i> <a href="https://lexariabioscience.com/2021/12/08/lexarias-dehydratechtm-cbd-reduces-arterial-stiffness-results-confirmed-in-human-clinical-study-hyper-h21-2/">December 8, 2021</a></span> </div> <div class="ts-blog-post-cat ts-blog-post-cat-above-title"> <span class="ts-meta-line cat-links"><span class="screen-reader-text ts-hide">Categories </span> <i class="ts-labtechco-icon-category"></i> <a href="https://lexariabioscience.com/category/press-releases/">Press Releases</a></span> </div> <div class="themestek-box-title"><h4><a href="https://lexariabioscience.com/2021/12/08/lexarias-dehydratechtm-cbd-reduces-arterial-stiffness-results-confirmed-in-human-clinical-study-hyper-h21-2/">Lexaria’s DehydraTECHTM-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2</a></h4></div> </div> <!-- Blog classic meta End --> <div class="entry-content"> <div class="themestek-box-desc-text"><div class="b2iNewsItemBodyDiv"><p><i><strong>Results suggest broader applications for DehydraTECH-CBD beyond hypertension</strong></i></p><p><strong>KELOWNA, BC / December 8, 2021</strong> / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to issue follow-up results from human clinical study HYPER-H21-2 confirming that DehydraTECH<sup>TM</sup>-processed cannabidiol ("CBD") reduces arterial stiffness, potentially broadening its application to treatment of cardiovascular and other disease states beyond hypertension where it has already shown tremendous promise.</p><p>"Reducing arterial stiffness in Lexaria's recent hypertension study after only a single day of dosing with our DehydraTECH-CBD is a major discovery," said John Docherty, President of Lexaria. "We know that increased arterial stiffness is correlated with many serious and life-threatening diseases affecting people worldwide, and we are optimistic that our latest findings could have future widespread implications for promotion of improved human health and wellness."</p><p><a href="https://pr.report/B3n9U7TL">Arterial stiffness is a strong predictor of many aspects of human disease</a>. The impacts of increased arterial stiffness are not limited only to coronary heart disease such as hypertension, but also include other disease states such as diabetes mellitus, renal disease and more. It can also be a prognostic marker for cardiovascular events and all-cause mortality, even in asymptomatic individuals without overt cardiovascular disease.</p><p>The efficacy of blood pressure treatment and differences in efficacy between different types of antihypertensive agents is strongly correlated with measuring arterial stiffness, whereby the significant blood pressure reduction effects as previously reported with DehydraTECH-CBD from study HYPER-H21-2 appear to have been at least partially due to these improvements in arterial stiffness.</p><p>The arterial stiffness findings from study HYPER-H21-2 are summarized in the table below. Arterial stiffness was measured through pulse wave velocity ("PWV") evaluation, together with assessments of augmentation index and pressure. All comparisons between DehydraTECH-CBD and placebo were statistically significant (p < 0.01).</p><figure class="table"><table style="border-bottom:none;border-left:none;border-right:none;border-top:none"><tbody><tr><td style="border-bottom:1.0pt solid windowtext;border-left:1.0pt solid windowtext;border-right:1.0pt solid windowtext;border-top:1.0pt solid windowtext;height:13.95pt;padding:0cm 5.4pt;vertical-align:top;width:212.4pt"> </td><td style="border-bottom:1.0pt solid windowtext;border-left:1.0pt none windowtext;border-right:1.0pt solid windowtext;border-top:1.0pt solid windowtext;height:13.95pt;padding:0cm 5.4pt;vertical-align:top;width:4.0cm"><p style="text-align:center">DehydraTECH-CBD</p></td><td style="border-bottom:1.0pt solid windowtext;border-left:1.0pt none windowtext;border-right:1.0pt solid windowtext;border-top:1.0pt solid windowtext;height:13.95pt;padding:0cm 5.4pt;vertical-align:top;width:106.3pt"><p style="text-align:center">Placebo</p></td></tr><tr><td style="border-bottom:1.0pt solid windowtext;border-left:1.0pt solid windowtext;border-right:1.0pt solid windowtext;border-top:1.0pt none windowtext;height:13.95pt;padding:0cm 5.4pt;vertical-align:top;width:212.4pt">Pulse Wave Velocity (PWV)</td><td style="border-bottom:1.0pt solid windowtext;border-left:none;border-right:1.0pt solid windowtext;border-top:none;height:13.95pt;padding:0cm 5.4pt;vertical-align:top;width:4.0cm"><p style="text-align:center">8.1 ± 0.3 m/s</p></td><td style="border-bottom:1.0pt solid windowtext;border-left:none;border-right:1.0pt solid windowtext;border-top:none;height:13.95pt;padding:0cm 5.4pt;vertical-align:top;width:106.3pt"><p style="text-align:center">8.3 ± 0.3 m/s</p></td></tr><tr><td style="border-bottom:1.0pt solid windowtext;border-left:1.0pt solid windowtext;border-right:1.0pt solid windowtext;border-top:1.0pt none windowtext;height:14.5pt;padding:0cm 5.4pt;vertical-align:top;width:212.4pt">Augmentation Index (Alx)</td><td style="border-bottom:1.0pt solid windowtext;border-left:none;border-right:1.0pt solid windowtext;border-top:none;height:14.5pt;padding:0cm 5.4pt;vertical-align:top;width:4.0cm"><p style="text-align:center">28.4 ± 1.4%</p></td><td style="border-bottom:1.0pt solid windowtext;border-left:none;border-right:1.0pt solid windowtext;border-top:none;height:14.5pt;padding:0cm 5.4pt;vertical-align:top;width:106.3pt"><p style="text-align:center">32.3 ± 1.3%</p></td></tr><tr><td style="border-bottom:1.0pt solid windowtext;border-left:1.0pt solid windowtext;border-right:1.0pt solid windowtext;border-top:1.0pt none windowtext;height:13.95pt;padding:0cm 5.4pt;vertical-align:top;width:212.4pt">Augmentation Index corrected to heart rate of 75 BPM (Alx.75)</td><td style="border-bottom:1.0pt solid windowtext;border-left:none;border-right:1.0pt solid windowtext;border-top:none;height:13.95pt;padding:0cm 5.4pt;vertical-align:top;width:4.0cm"><p style="text-align:center">27.8 ± 1.3%</p></td><td style="border-bottom:1.0pt solid windowtext;border-left:none;border-right:1.0pt solid windowtext;border-top:none;height:13.95pt;padding:0cm 5.4pt;vertical-align:top;width:106.3pt"><p style="text-align:center">30.4 ± 1.3%</p></td></tr><tr><td style="border-bottom:1.0pt solid windowtext;border-left:1.0pt solid windowtext;border-right:1.0pt solid windowtext;border-top:1.0pt none windowtext;height:13.95pt;padding:0cm 5.4pt;vertical-align:top;width:212.4pt">Augmentation Pressure (AugP)</td><td style="border-bottom:1.0pt solid windowtext;border-left:none;border-right:1.0pt solid windowtext;border-top:none;height:13.95pt;padding:0cm 5.4pt;vertical-align:top;width:4.0cm"><p style="text-align:center">12.0 ± 1.0 mmHg</p></td><td style="border-bottom:1.0pt solid windowtext;border-left:none;border-right:1.0pt solid windowtext;border-top:none;height:13.95pt;padding:0cm 5.4pt;vertical-align:top;width:106.3pt"><p style="text-align:center">14.6 ± 1.0 mmHg</p></td></tr></tbody></table></figure><p>In the table above, smaller numbers are the objective. PWV values normally <a href="https://pr.report/sGhEuKAc">increase by 0.9 m/s every 10 years</a> between the age of 45 and 60 as arterial stiffness increases with aging. It has been estimated that a 1.0 m/s increase in PWV accounts for a <a href="https://pr.report/OYIHhb0P">15% increase in cardiovascular and all-case mortality</a>.</p><p>To have decreased arterial stiffness to the degree demonstrated in our present study after only a single day of dosing with DehydraTECH-CBD is quite remarkable and will be more thoroughly investigated in Lexaria's upcoming 6-week hypertension study HYPER-H21-4, where multiple doses over this period are expected to demonstrate additional benefits against hypertension and arterial stiffness.</p><p>As first reported on September 7, 2021, at selected times during study HYPER-H21-2, some volunteers with mild to moderate hypertension had reductions of as much as a 20 mmHg (i.e., 23%) drop in blood pressure relative to placebo. When averaged over the 24-hour duration of the study, reductions in diastolic, systolic and mean arterial pressure were all significantly evidenced with DehydraTECH-CBD when compared to the placebo condition. All secondary objectives of human clinical study HYPER-H21-2 have now been successfully completed</p><p><strong>About DehydraTECH-CBD</strong></p><p>DehydraTECH-CBD is a unique CBD formulation Lexaria has developed and is optimizing based on its patented and proprietary DehydraTECH drug delivery technology. DehydraTECH is designed to improve the way active molecules enter the bloodstream upon oral ingestion. DehydraTECH has also demonstrated enhanced delivery of certain active molecules including CBD into brain tissue, which Lexaria believes to be of particular importance for the effectiveness of its DehydraTECH-CBD specifically against hypertension because of the significant <a href="https://pr.report/3ndrY6Gl">influence of central mediation</a> upon blood pressure.</p><p><strong>About Human Study HYPER-H21-2</strong></p><p>Human Study HYPER-H21-2 was conducted at a European medical research hospital. Sixteen human volunteers (8 male; 8 female) aged 45-65 with otherwise untreated pre- or mild-hypertension were given either a placebo, or three separate doses of 150 mg each of DehydraTECH-CBD over a 14-hour period and studied over a 24-hour duration. The average weight and height were 91 ± 13 kg and 173 ± 9 cm. Ambulatory blood pressure was recorded for 24 hours.</p><p><strong>Hypertension Markets</strong></p><p>The hypertension market is valued at <a href="https://pr.report/2kMKamZO">$28 billion per year</a> and is expected to continue growing as one of the world's top health problems. Geographically, some of the highest rates of growth are expected in more recently industrialized nations such as China and India. <a href="https://pr.report/eaovpxTy">Over 1.1 billion people</a> worldwide suffer from hypertension - elevated blood pressure. Hypertension is a major risk factor for cardiovascular and cerebrovascular disease, and accounts for approximately 45% of cardiovascular disease <a href="https://pr.report/OF7E3Il2">mortality and morbidity worldwide</a>.</p><p>Drugs focused on blood pressure and related conditions are some of the <a href="https://pr.report/gvOeiXCP">highest selling drugs</a> in the world. Lipitor, used to treat high cholesterol and reduce the risk of heart disease, has generated $94.7 billion in revenue from 1992 until 2017. Plavix, used to prevent heart attack and stroke, has sold $46.5 billion from 1992 until 2017. There are <a href="https://pr.report/epi6bUzn">several hypertension drugs</a> that each generate $1 billion per year or more in revenue.</p><p><strong>About Lexaria Bioscience Corp.</strong></p><p>Lexaria Bioscience Corp.'s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 23 patents granted and over 50 patents pending worldwide. For more information, please visit <a href="https://pr.report/m6ALw8Vq">www.lexariabioscience.com</a>.</p><p><strong>CAUTION REGARDING FORWARD-LOOKING STATEMENTS</strong></p><p>This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.</p><p><strong>INVESTOR CONTACT:</strong></p><p><a href="/cdn-cgi/l/email-protection#076e75476b627f66756e66656e6874646e626964622964686a"><span class="__cf_email__" data-cfemail="761f04361a130e17041f17141f1905151f131815135815191b">[email protected]</span></a><br>Phone: 250-765-6424, ext 202</p><p><strong>SOURCE:</strong> Lexaria Bioscience Corp.</p><br><br>View source version on accesswire.com: <br><a href='https://www.accesswire.com/676498/Lexarias-DehydraTECHTM-CBD-Reduces-Arterial-Stiffness-Results-Confirmed-in-Human-Clinical-Study-HYPER-H21-2'>https://www.accesswire.com/676498/Lexarias-DehydraTECHTM-CBD-Reduces-Arterial-Stiffness-Results-Confirmed-in-Human-Clinical-Study-HYPER-H21-2</a><br><br><img src='https://www.accesswire.com/img.ashx?id=676498' /></div></div> <div class="themestek-blog-classic-footer-readmore"> <div class="themestek-blogbox-footer-left"><a href="https://lexariabioscience.com/2021/12/08/lexarias-dehydratechtm-cbd-reduces-arterial-stiffness-results-confirmed-in-human-clinical-study-hyper-h21-2/">Read More</a></div> </div> <div class="ts-footer-meta-wrapper"> <span class="ts-footer-meta-line-w ts-footer-meta-line-comments"> <a href="https://lexariabioscience.com/2021/12/08/lexarias-dehydratechtm-cbd-reduces-arterial-stiffness-results-confirmed-in-human-clinical-study-hyper-h21-2/"> <i class="ts-labtechco-icon-comment-1"></i> <span class="comments"> 0 Comments </span> </a> </span> <span class="ts-footer-meta-line-w ts-footer-meta-line-author"> <span class="author vcard"> <span class="screen-reader-text ts-hide">Author </span> <a class="url fn n" href="https://lexariabioscience.com/author/mmcdonald/"><i class="ts-labtechco-icon-user"></i> mmcdonald</a> </span> </span> </div> </div><!-- .entry-content --> </div><!-- .ts-blog-classic-box-content --> </article><!-- #post-## --> <div class="clearfix"></div> </main><!-- .site-main --> </div><!-- .content-area --> <aside id="sidebar-right" class="widget-area col-md-3 col-lg-3 col-xs-12 sidebar"> <aside id="search-2" class="widget-even widget-6 widget widget_search"><form role="search" method="get" class="search-form" action="https://lexariabioscience.com/"> <label> <span class="screen-reader-text">Search for:</span> <input type="search" class="search-field" placeholder="Search …" value="" name="s" /> </label> <input type="submit" class="search-submit" value="Search" /> </form></aside><aside id="categories-2" class="widget-odd widget-7 widget widget_categories"><h3 class="widget-title">Categories</h3> <ul> <li class="cat-item cat-item-37"><a href="https://lexariabioscience.com/category/press-releases/">Press Releases</a> <span>169</span> </li> </ul> </aside> <aside id="themestek-recent-posts-2" class="widget-even widget-8 widget themestek_widget_recent_entries"> <h3 class="widget-title">Recent Posts</h3> <ul class="ts-recent-post-list"> <li class="ts-recent-post-list-li"><a href="https://lexariabioscience.com/2025/02/11/lexaria-granted-two-new-dehydratech-patents-for-treatment-of-epilepsy/">Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy</a><span class="post-date">February 11, 2025</span></li><li class="ts-recent-post-list-li"><a href="https://lexariabioscience.com/2025/02/06/lexaria-biodistribution-study-for-dehydratech-glp-1-is-underway/">Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway</a><span class="post-date">February 6, 2025</span></li><li class="ts-recent-post-list-li"><a href="https://lexariabioscience.com/2025/02/05/lexaria-updates-its-ongoing-human-study-glp-1-h24-4/">Lexaria Updates its Ongoing Human Study GLP-1-H24-4</a><span class="post-date">February 5, 2025</span></li><li class="ts-recent-post-list-li"><a href="https://lexariabioscience.com/2025/01/30/lexaria-releases-annual-letter-from-the-ceo-3/">Lexaria Releases Annual Letter from the CEO</a><span class="post-date">January 30, 2025</span></li><li class="ts-recent-post-list-li"><a href="https://lexariabioscience.com/2025/01/15/lexarias-human-glp-1-study-5-receives-independent-review-board-approval/">Lexaria’s Human GLP-1 Study #5 Receives Independent Review Board Approval</a><span class="post-date">January 15, 2025</span></li> </ul> </aside> <aside id="archives-3" class="widget-even widget-10 widget widget_archive"><h3 class="widget-title">Archives</h3> <ul> <li><a href='https://lexariabioscience.com/2025/02/'>February 2025</a></li> <li><a href='https://lexariabioscience.com/2025/01/'>January 2025</a></li> <li><a href='https://lexariabioscience.com/2024/12/'>December 2024</a></li> <li><a href='https://lexariabioscience.com/2024/11/'>November 2024</a></li> <li><a href='https://lexariabioscience.com/2024/10/'>October 2024</a></li> <li><a href='https://lexariabioscience.com/2024/09/'>September 2024</a></li> <li><a href='https://lexariabioscience.com/2024/08/'>August 2024</a></li> <li><a href='https://lexariabioscience.com/2024/07/'>July 2024</a></li> <li><a href='https://lexariabioscience.com/2024/06/'>June 2024</a></li> <li><a href='https://lexariabioscience.com/2024/05/'>May 2024</a></li> <li><a href='https://lexariabioscience.com/2024/04/'>April 2024</a></li> <li><a href='https://lexariabioscience.com/2024/03/'>March 2024</a></li> <li><a href='https://lexariabioscience.com/2024/02/'>February 2024</a></li> <li><a href='https://lexariabioscience.com/2024/01/'>January 2024</a></li> <li><a href='https://lexariabioscience.com/2023/12/'>December 2023</a></li> <li><a href='https://lexariabioscience.com/2023/11/'>November 2023</a></li> <li><a href='https://lexariabioscience.com/2023/10/'>October 2023</a></li> <li><a href='https://lexariabioscience.com/2023/09/'>September 2023</a></li> <li><a href='https://lexariabioscience.com/2023/08/'>August 2023</a></li> <li><a href='https://lexariabioscience.com/2023/07/'>July 2023</a></li> <li><a href='https://lexariabioscience.com/2023/06/'>June 2023</a></li> <li><a href='https://lexariabioscience.com/2023/05/'>May 2023</a></li> <li><a href='https://lexariabioscience.com/2023/04/'>April 2023</a></li> <li><a href='https://lexariabioscience.com/2023/03/'>March 2023</a></li> <li><a href='https://lexariabioscience.com/2023/02/'>February 2023</a></li> <li><a href='https://lexariabioscience.com/2023/01/'>January 2023</a></li> <li><a href='https://lexariabioscience.com/2022/12/'>December 2022</a></li> <li><a href='https://lexariabioscience.com/2022/11/'>November 2022</a></li> <li><a href='https://lexariabioscience.com/2022/10/'>October 2022</a></li> <li><a href='https://lexariabioscience.com/2022/09/'>September 2022</a></li> <li><a href='https://lexariabioscience.com/2022/08/'>August 2022</a></li> <li><a href='https://lexariabioscience.com/2022/07/'>July 2022</a></li> <li><a href='https://lexariabioscience.com/2022/06/'>June 2022</a></li> <li><a href='https://lexariabioscience.com/2022/05/'>May 2022</a></li> <li><a href='https://lexariabioscience.com/2022/04/'>April 2022</a></li> <li><a href='https://lexariabioscience.com/2022/03/'>March 2022</a></li> <li><a href='https://lexariabioscience.com/2022/02/'>February 2022</a></li> <li><a href='https://lexariabioscience.com/2022/01/'>January 2022</a></li> <li><a href='https://lexariabioscience.com/2021/12/' aria-current="page">December 2021</a></li> <li><a href='https://lexariabioscience.com/2021/11/'>November 2021</a></li> <li><a href='https://lexariabioscience.com/2021/10/'>October 2021</a></li> <li><a href='https://lexariabioscience.com/2021/09/'>September 2021</a></li> <li><a href='https://lexariabioscience.com/2021/07/'>July 2021</a></li> <li><a href='https://lexariabioscience.com/2021/06/'>June 2021</a></li> <li><a href='https://lexariabioscience.com/2021/05/'>May 2021</a></li> <li><a href='https://lexariabioscience.com/2021/04/'>April 2021</a></li> <li><a href='https://lexariabioscience.com/2021/03/'>March 2021</a></li> <li><a href='https://lexariabioscience.com/2021/02/'>February 2021</a></li> <li><a href='https://lexariabioscience.com/2021/01/'>January 2021</a></li> </ul> </aside></aside><!-- #sidebar-right --> </div><!-- .site-content-inner --> </div><!-- .site-content --> </div><!-- .site-content-wrapper --> <footer id="colophon" class="site-footer "> <div class="footer_inner_wrapper footer ts-bg ts-bgcolor-grey ts-bgimage-no"> <div class="site-footer-bg-layer ts-bg-layer"></div> <div class="site-footer-w"> <div class="footer-rows"> <div class="footer-rows-inner"> <div id="first-footer" class="sidebar-container first-footer ts-bg ts-bgcolor-grey ts-textcolor-dark ts-bgimage-no" role="complementary"> <div class="first-footer-bg-layer ts-bg-layer"></div> <div class="container"> <div class="first-footer-inner"> <div class="row multi-columns-row"> <div class="widget-area col-xs-12 col-sm-4 col-md-4 col-lg-4 first-widget-area"> <aside id="block-11" class="widget-odd widget-5 widget widget_block widget_media_image"> <figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" src="https://lexariabioscience.com/wp-content/uploads/2022/03/Lexaria_Bioscience_Logo_Dark_WEB.png" alt="" class="wp-image-7760" width="180" height="95" srcset="https://lexariabioscience.com/wp-content/uploads/2022/03/Lexaria_Bioscience_Logo_Dark_WEB.png 418w, https://lexariabioscience.com/wp-content/uploads/2022/03/Lexaria_Bioscience_Logo_Dark_WEB-300x158.png 300w" sizes="auto, (max-width: 180px) 100vw, 180px" /></figure> </aside><aside id="block-2" class="widget-even widget-6 widget widget_block widget_text"> <p>Lexaria Bioscience Corp. (NASDAQ:LEXX) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.</p> </aside> </div><!-- .widget-area --> <div class="widget-area col-xs-12 col-sm-4 col-md-4 col-lg-4 first-widget-area"> <aside id="block-35" class="widget-odd widget-5 widget widget_block widget_text"> <p><a href="tel:+12507656424">250.765.6424</a><br><a href="/cdn-cgi/l/email-protection#0960676f6649656c71687b60686b60667a6a606c676a6c276a6664"><span class="__cf_email__" data-cfemail="137a7d757c537f766b72617a72717a7c60707a767d70763d707c7e">[email protected]</span></a></p> </aside><aside id="block-37" class="widget-even widget-6 widget widget_block widget_text"> <p><b>Canadian Operations</b><br>#100-740 McCurdy Road<br>Kelowna, BC, V1X2P7<br><br><strong>US Operations</strong><br>105 Peach State Court, Suite A<br>Tyrone, GA 30290</p> </aside><aside id="block-31" class="widget-odd widget-7 widget widget_block widget_text"> <p><a href="https://lexariabioscience.com/privacy-policy/">Privacy Policy</a></p> </aside><aside id="block-13" class="widget-even widget-8 widget widget_block"><p><ul id="" class="cnss-social-icon " style="text-align:left;"><li class="cn-fa-facebook cn-fa-icon " style="display:inline-block;"><a class="" target="_blank" href="https://www.facebook.com/lexariabioscience" title="facebook" style="width:28px;height:28px;padding:5px 0;margin:6px;color: #ffffff;border-radius: 0%;"><i title="facebook" style="font-size:18px;" class="fab fa-facebook"></i></a></li><li class="cn-fa-twitter cn-fa-icon " style="display:inline-block;"><a class="" target="_blank" href="https://twitter.com/lexariabiocorp" title="twitter" style="width:28px;height:28px;padding:5px 0;margin:6px;color: #ffffff;border-radius: 0%;"><i title="twitter" style="font-size:18px;" class="fab fa-twitter"></i></a></li><li class="cn-fa-linkedin cn-fa-icon " style="display:inline-block;"><a class="" target="_blank" href="https://www.linkedin.com/company/lexaria-bioscience/" title="linkedin" style="width:28px;height:28px;padding:5px 0;margin:6px;color: #ffffff;border-radius: 0%;"><i title="linkedin" style="font-size:18px;" class="fab fa-linkedin"></i></a></li></ul></p> </aside> </div><!-- .widget-area --> <div class="widget-area col-xs-12 col-sm-4 col-md-4 col-lg-4 first-widget-area"> <aside id="block-10" class="widget-even widget-2 widget widget_block widget_text"> <p><strong>General Disclaimer:</strong><br>No statement in this web site has been evaluated by the Food and Drug Administration (FDA). Furthermore, none of the statements in this web site should be construed as dispensing medical advice or making claims regarding the cure of diseases…<br><br><a href="https://lexariabioscience.com/general-disclaimer/">Read More</a></p> </aside> </div><!-- .widget-area --> </div><!-- .row.multi-columns-row --> </div><!-- .first-footer-inner --> </div><!-- --> </div><!-- #secondary --> </div><!-- .footer-inner --> </div><!-- .footer --> <div id="bottom-footer-text" class="bottom-footer-text ts-bottom-footer-text site-info ts-bg ts-bgcolor-transparent ts-textcolor-dark ts-bgimage-no"> <div class="bottom-footer-bg-layer ts-bg-layer"></div> <div class="container"> <div class="bottom-footer-inner"> <div class="row multi-columns-row"> <div class="col-xs-12 col-sm-12 ts-footer2-left "> Copyright © 2024 <a href="https://lexariabioscience.com">Lexaria Bioscience</a>. All rights reserved. </div><!-- footer left --> </div><!-- .row.multi-columns-row --> </div><!-- .bottom-footer-inner --> </div><!-- --> </div><!-- .footer-text --> </div><!-- .footer-inner-wrapper --> </div><!-- .site-footer-inner --> </footer><!-- .site-footer --> </div><!-- #page .site --> </div><!-- .main-holder --> <!-- To Top --> <a id="totop" href="#top"><i class="ts-labtechco-icon-angle-up"></i></a> <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script> window.RS_MODULES = window.RS_MODULES || {}; window.RS_MODULES.modules = window.RS_MODULES.modules || {}; window.RS_MODULES.waiting = window.RS_MODULES.waiting || []; window.RS_MODULES.defered = true; window.RS_MODULES.moduleWaiting = window.RS_MODULES.moduleWaiting || {}; window.RS_MODULES.type = 'compiled'; </script> <script> var _paq = _paq || []; _paq.push(['trackPageView']); (function () { var u = "https://stats1.wpmudev.com/"; _paq.push(['setTrackerUrl', u + 'track/']); _paq.push(['setSiteId', '102684']); var d = document, g = d.createElement('script'), s = d.getElementsByTagName('script')[0]; g.type = 'text/javascript'; g.async = true; g.defer = true; g.src = 'https://stats.wpmucdn.com/analytics.js'; s.parentNode.insertBefore(g, s); })(); </script> <script>(function(){var s=document.createElement('script');var e = !document.body ? document.querySelector('head'):document.body;s.src='https://acsbapp.com/apps/app/dist/js/app.js';s.setAttribute('data-source', 'WordPress');s.setAttribute('data-plugin-version', '2.6');s.defer=true;s.onload=function(){acsbJS.init({ statementLink : '', footerHtml : '', hideMobile : false, hideTrigger : false, language : 'en', position : 'right', leadColor : '#3a5dae', triggerColor : '#3a5dae', triggerRadius : '50%', triggerPositionX : 'right', triggerPositionY : 'top', triggerIcon : 'people', triggerSize : 'medium', triggerOffsetX : 15, triggerOffsetY : 50, mobile : { triggerSize : 'small', triggerPositionX : 'right', triggerPositionY : 'bottom', triggerOffsetX : 10, triggerOffsetY : 10, triggerRadius : '50%' } }); }; e.appendChild(s);}());</script><script> jQuery('#popmake-8310').find('.ts-vc_btn3').click(function() { document.cookie = "pum-8310=true;"; }); </script><link rel='stylesheet' id='rs-plugin-settings-css' href='https://lexariabioscience.com/wp-content/plugins/revslider/public/assets/css/rs6.css?ver=6.5.15' media='all' /> <style id='rs-plugin-settings-inline-css'> #rs-demo-id {} </style> <script src="https://lexariabioscience.com/wp-includes/js/jquery/ui/core.min.js?ver=1.13.3" id="jquery-ui-core-js"></script> <script src="https://lexariabioscience.com/wp-includes/js/jquery/ui/mouse.min.js?ver=1.13.3" id="jquery-ui-mouse-js"></script> <script src="https://lexariabioscience.com/wp-includes/js/jquery/ui/sortable.min.js?ver=1.13.3" id="jquery-ui-sortable-js"></script> <script src="https://lexariabioscience.com/wp-includes/js/dist/hooks.min.js?ver=4d63a3d491d11ffd8ac6" id="wp-hooks-js"></script> <script src="https://lexariabioscience.com/wp-includes/js/dist/i18n.min.js?ver=5e580eb46a90c2b997e6" id="wp-i18n-js"></script> <script id="wp-i18n-js-after"> /* <![CDATA[ */ wp.i18n.setLocaleData( { 'text direction\u0004ltr': [ 'ltr' ] } ); /* ]]> */ </script> <script src="https://lexariabioscience.com/wp-content/plugins/contact-form-7/includes/swv/js/index.js?ver=6.0.3" id="swv-js"></script> <script id="contact-form-7-js-before"> /* <![CDATA[ */ var wpcf7 = { "api": { "root": "https:\/\/lexariabioscience.com\/wp-json\/", "namespace": "contact-form-7\/v1" } }; /* ]]> */ </script> <script src="https://lexariabioscience.com/wp-content/plugins/contact-form-7/includes/js/index.js?ver=6.0.3" id="contact-form-7-js"></script> <script src="https://lexariabioscience.com/wp-content/plugins/revslider/public/assets/js/rbtools.min.js?ver=6.5.15" defer async id="tp-tools-js"></script> <script src="https://lexariabioscience.com/wp-content/plugins/revslider/public/assets/js/rs6.min.js?ver=6.5.15" defer async id="revmin-js"></script> <script src="https://lexariabioscience.com/wp-content/themes/labtechco/libraries/perfect-scrollbar/perfect-scrollbar.jquery.min.js?ver=6.7.2" id="perfect-scrollbar-js"></script> <script src="https://lexariabioscience.com/wp-content/themes/labtechco/libraries/select2/select2.min.js?ver=6.7.2" id="ts-select2-js"></script> <script src="https://lexariabioscience.com/wp-content/plugins/js_composer/assets/lib/vendor/node_modules/isotope-layout/dist/isotope.pkgd.min.js?ver=7.7.2" id="isotope-js"></script> <script src="https://lexariabioscience.com/wp-content/themes/labtechco/libraries/jquery-mousewheel/jquery.mousewheel.min.js?ver=6.7.2" id="jquery-mousewheel-js"></script> <script src="https://lexariabioscience.com/wp-content/plugins/js_composer/assets/lib/vendor/node_modules/flexslider/jquery.flexslider-min.js?ver=7.7.2" id="flexslider-js"></script> <script src="https://lexariabioscience.com/wp-content/themes/labtechco/libraries/sticky-kit/jquery.sticky-kit.min.js?ver=6.7.2" id="sticky-kit-js"></script> <script src="https://lexariabioscience.com/wp-content/themes/labtechco/libraries/slick/slick.min.js?ver=6.7.2" id="slick-js"></script> <script src="https://lexariabioscience.com/wp-content/plugins/js_composer/assets/lib/vendor/prettyphoto/js/jquery.prettyPhoto.min.js?ver=7.7.2" id="prettyphoto-js"></script> <script src="https://lexariabioscience.com/wp-content/plugins/js_composer/assets/js/dist/js_composer_front.min.js?ver=7.7.2" id="wpb_composer_front_js-js"></script> <script id="labtechco-script-js-extra"> /* <![CDATA[ */ var ts_labtechco_js_vars = {"ts_breakpoint":"1200","ajaxurl":"https:\/\/lexariabioscience.com\/wp-admin\/admin-ajax.php"}; /* ]]> */ </script> <script src="https://lexariabioscience.com/wp-content/themes/labtechco/js/scripts.min.js?ver=1.0" id="labtechco-script-js"></script> <script></script><!-- start Simple Custom CSS and JS --> <script> jQuery(document).ready(function() { var target = document.querySelector('.site-header-menu-inner'); if (target) { var observer = new MutationObserver(function(mutationsList) { mutationsList.forEach(function(mutation) { if (mutation.type === 'attributes' && mutation.attributeName === 'class') { if (jQuery(target).hasClass('is_stuck')) { // console.log('.is_stuck class added'); jQuery('.investor-menu').addClass('sticky-nav'); } else { // console.log('.is_stuck class removed'); jQuery('.investor-menu').removeClass('sticky-nav'); } } }); }); observer.observe(target, { attributes: true }); } });</script> <!-- end Simple Custom CSS and JS --> <!-- start Simple Custom CSS and JS --> <script> // JavaScript to toggle the menu document.addEventListener('DOMContentLoaded', function() { var hamburger = document.querySelector('.hamburger'); var menu = document.querySelector('.investor-menu ul.menu'); hamburger.addEventListener('click', function() { menu.classList.toggle('active'); }); }); </script> <!-- end Simple Custom CSS and JS --> </body> </html>